<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>GEODON - ziprasidone mesylate injection, powder, lyophilized, for solution </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>These highlights do not include all the information needed to use GEODON safely and effectively. See full prescribing information for GEODON.GEODON® (ziprasidone HCl) capsulesGEODON® (ziprasidone mesylate) injection for intramuscular useInitial U.S. Approval: 2001</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="section-1"></a><p></p>
<h1>BOXED WARNING</h1>
<p class="First"></p>
<p><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients of between 1.6 to 1.7 times the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were varied, most of the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> appeared to be either cardiovascular (e.g., <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>) or infectious (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. GEODON (ziprasidone) is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1)</a></span>]).</span></p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<p class="First"></p>
<p>GEODON is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, as monotherapy for the acute treatment of bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. GEODON intramuscular is indicated for acute <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> in schizophrenic patients. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [<span class="Italics">see <a href="#S5.2">Warnings and Precautions (5.2)</a></span>]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>-type <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, a potentially fatal <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">polymorphic ventricular tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> or increase the rate of <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> is not yet known [<span class="Italics">see <a href="#S5.2">Warnings and Precautions (5.2)</a></span>]</p>
<p>
 
</p>
<p></p>
<p>Geodon is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. The efficacy of oral ziprasidone was established in four short-term (4- and 6-week) controlled trials of adult schizophrenic inpatients and in one maintenance trial of stable adult schizophrenic inpatients [<span class="Italics">see <a href="#S14.1">Clinical Studies (14.1)</a></span>].</p>
<p>
 
</p>
<p></p>
<p>Geodon is indicated as monotherapy for the acute treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span>. Efficacy was established in two 3-week monotherapy studies in adult patients [<span class="Italics">see <a href="#S14.2">Clinical Studies (14.2)</a></span>]<span class="Italics">.</span></p>
<p>Geodon is indicated as an adjunct to lithium or valproate for the maintenance treatment of <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span>. Efficacy was established in a maintenance trial in adult patients. The efficacy of Geodon as monotherapy for the maintenance treatment of <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> has not been systematically evaluated in controlled clinical trials [<span class="Italics">see <a href="#S14.2">Clinical Studies (14.2)</a></span>].</p>
<p>
 
</p>
<p></p>
<p>GEODON intramuscular is indicated for the treatment of acute <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> in schizophrenic patients for whom treatment with ziprasidone is appropriate and who need intramuscular antipsychotic medication for rapid control of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>. The efficacy of intramuscular ziprasidone for acute <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> was established in single day controlled trials of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> schizophrenic inpatients [<span class="Italics">see <a href="#S14.1">Clinical Trials (14.1)</a></span>]</p>
<p>"<span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Psychomotor agitation</span>" is defined in DSM-IV as "excessive motor activity associated with a feeling of inner <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>". Schizophrenic patients experiencing <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>.</p>
<p>Since there is no experience regarding the safety of administering ziprasidone intramuscular to schizophrenic patients already taking oral ziprasidone, the practice of co-administration is not recommended.</p>
<p>Ziprasidone intramuscular is intended for intramuscular use only and should not be administered intravenously.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<p class="First"></p>
<p>Give oral doses with food.</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span>: Initiate at 20 mg twice daily. Daily dosage may be adjusted up to 80 mg twice daily. Dose adjustments should occur at intervals of not less than 2 days. Safety and efficacy has been demonstrated in doses up to 100 mg twice daily. The lowest effective dose should be used. (<a href="#S2.1">2.1</a>)</li>
<li>Acute treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>/mixed episodes of <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span>: Initiate at 40 mg twice daily. Increase to 60 mg or 80 mg twice daily on day 2 of treatment. Subsequent dose adjustments should be based on tolerability and efficacy within the range of 40–80 mg twice daily. (<a href="#S2.2">2.2</a>)</li>
<li>Maintenance treatment of <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> as an adjunct to lithium or valproate: Continue treatment at the same dose on which the patient was initially stabilized, within the range of 40–80 mg twice daily. (<a href="#S2.2">2.2</a>)</li>
<li>Acute treatment of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> associated with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (intramuscular administration): 10 mg–20 mg up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every 2 hours. Doses of 20 mg may be administered every 4 hours. (<a href="#S2.3">2.3</a>)</li>
</ul>
<p>
 
</p>
<p></p>
<p><span class="Underline">Dose Selection </span></p>
<p>GEODON Capsules should be administered at an initial daily dose of 20 mg twice daily with food. In some patients, daily dosage may subsequently be adjusted on the basis of individual clinical status up to 80 mg twice daily. Dosage adjustments, if indicated, should generally occur at intervals of not less than 2 days, as steady-state is achieved within 1 to 3 days. In order to ensure use of the lowest effective dose, patients should ordinarily be observed for improvement for several weeks before upward dosage adjustment.</p>
<p> Efficacy in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> was demonstrated in a dose range of 20 mg to 100 mg twice daily in short-term, placebo-controlled clinical trials. There were trends toward dose response within the range of 20 mg to 80 mg twice daily, but results were not consistent. An increase to a dose greater than 80 mg twice daily is not generally recommended. The safety of doses above 100 mg twice daily has not been systematically evaluated in clinical trials [<span class="Italics">see <a href="#S14.1">Clinical Studies (14.1)</a></span>].</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Maintenance Treatment</span></p>
<p>While there is no body of evidence available to answer the question of how long a patient treated with ziprasidone should remain on it, a maintenance study in patients who had been symptomatically stable and then randomized to continue ziprasidone or switch to placebo demonstrated a delay in time to relapse for patients receiving Geodon [<span class="Italics">see <a href="#S14.1">Clinical Studies (14.1)</a></span>]. No additional benefit was demonstrated for doses above 20 mg twice daily. Patients should be periodically reassessed to determine the need for maintenance treatment.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Acute Treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> or Mixed Episodes </span></p>
<p> Dose Selection--Oral ziprasidone should be administered at an initial daily dose of 40 mg twice daily with food. The dose may then be increased to 60 mg or 80 mg twice daily on the second day of treatment and subsequently adjusted on the basis of tolerance and efficacy within the range 40 mg–80 mg twice daily. In the flexible-dose clinical trials, the mean daily dose administered was approximately 120 mg [<span class="Italics">see <a href="#S14.2">Clinical Studies (14.2)</a></span>].</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Maintenance Treatment (as an adjunct to lithium or valproate)</span></p>
<p>Continue treatment at the same dose on which the patient was initially stabilized, within the range of 40 mg–80 mg twice daily with food. Patients should be periodically reassessed to determine the need for maintenance treatment [<span class="Italics">see <a href="#S14.2">Clinical Studies (14.2)</a></span>]<span class="Italics">.</span></p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Intramuscular Dosing </span></p>
<p>The recommended dose is 10 mg to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day. Intramuscular administration of ziprasidone for more than three consecutive days has not been studied.</p>
<p>If long-term therapy is indicated, oral ziprasidone hydrochloride capsules should replace the intramuscular administration as soon as possible.</p>
<p> Since there is no experience regarding the safety of administering ziprasidone intramuscular to schizophrenic patients already taking oral ziprasidone, the practice of co-administration is not recommended.</p>
<p>Ziprasidone intramuscular is intended for intramuscular use only and should not be administered intravenously.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Intramuscular Preparation for Administration </span></p>
<p> GEODON for Injection (ziprasidone mesylate) should only be administered by intramuscular injection and should not be administered intravenously. Single-dose vials require reconstitution prior to administration.</p>
<p>  Add 1.2 mL of Sterile Water for Injection to the vial and shake vigorously until all the drug is dissolved. Each mL of reconstituted solution contains 20 mg ziprasidone. To administer a 10 mg dose, draw up 0.5 mL of the reconstituted solution. To administer a 20 mg dose, draw up 1.0 mL of the reconstituted solution. Any unused portion should be discarded. Since no preservative or bacteriostatic agent is present in this product, aseptic technique must be used in preparation of the final solution. This medicinal product must not be mixed with other medicinal products or solvents other than Sterile Water for Injection. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Oral:</span> Dosage adjustments are generally not required on the basis of age, gender, race, or renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Geodon is not approved for use in children or adolescents.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Intramuscular:</span> Ziprasidone intramuscular has not been systematically evaluated in elderly patients or in patients with hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. As the cyclodextrin excipient is cleared by renal filtration, ziprasidone intramuscular should be administered with caution to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Dosing adjustments are not required on the basis of gender or race [<span class="Italics">see <a href="#S8">Use in Specific Populations (8)</a></span>].</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1>DOSAGE FORMS &amp; STRENGTHS</h1>
<p class="First"></p>
<p> GEODON Capsules are differentiated by capsule color/size and are imprinted in black ink with "Pfizer and ZDX [dosage strength]" or "Pfizer" and a unique number. GEODON Capsules are supplied for oral administration in 20 mg (blue/white), 40 mg (blue/blue), 60 mg (white/white), and 80 mg (blue/white) capsules. They are supplied in the following strengths and package configurations:</p>
<table width="100%">
<col align="center" span="1" valign="middle" width="25%">
<col align="center" span="1" valign="middle" width="20%">
<col align="center" span="1" valign="middle" width="10%">
<col align="center" span="1" valign="middle" width="25%">
<col align="center" span="1" valign="middle" width="20%">
<tbody class="Headless">
<tr class="First">
<th align="center" colspan="2">GEODON Capsules</th>
<th align="center" colspan="1">OR</th>
<th align="center" colspan="2">GEODON Capsules</th>
</tr>
<tr>
<th align="center" colspan="1">Capsule Strength (mg)</th>
<th align="center" colspan="1">Imprint</th>
<th align="center" colspan="1"></th>
<th align="center" colspan="1">Capsule Strength (mg)</th>
<th align="center" colspan="1">Imprint</th>
</tr>
<tr>
<td align="center"><span class="Bold">20</span></td>
<td align="center"><span class="Bold">ZDX 20</span></td>
<td align="center"></td>
<td align="center"><span class="Bold">20</span></td>
<td align="center"><span class="Bold">396</span></td>
</tr>
<tr>
<td align="center"><span class="Bold">40</span></td>
<td align="center"><span class="Bold">ZDX 40</span></td>
<td align="center"></td>
<td align="center"><span class="Bold">40</span></td>
<td align="center"><span class="Bold">397</span></td>
</tr>
<tr>
<td align="center"><span class="Bold">60</span></td>
<td align="center"><span class="Bold">ZDX 60</span></td>
<td align="center"></td>
<td align="center"><span class="Bold">60</span></td>
<td align="center"><span class="Bold">398</span></td>
</tr>
<tr class="Last">
<td align="center"><span class="Bold">80</span></td>
<td align="center"><span class="Bold">ZDX 80</span></td>
<td align="center"></td>
<td align="center"><span class="Bold">80</span></td>
<td align="center"><span class="Bold">399</span></td>
</tr>
</tbody>
</table>
<p>GEODON for Injection is available in a single-dose vial as ziprasidone mesylate (20 mg ziprasidone/mL when reconstituted according to label instructions) [<span class="Italics">see <a href="#S2.3">Dosage and Administration (2.3)</a></span>]. Each mL of ziprasidone mesylate for injection (when reconstituted) affords a colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> pink solution that contains 20 mg of ziprasidone and 4.7 mg of methanesulfonic acid solubilized by 294 mg of sulfobutylether β-cyclodextrin sodium (SBECD).</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"></p>
<ul>
<li> Do not use in patients with a known history of QT prolongation (<a href="#S4.1">4.1</a>)</li>
<li> Do not use in patients with recent <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> (<a href="#S4.1">4.1</a>)</li>
<li> Do not use in patients with uncompensated <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (<a href="#S4.1">4.1</a>)</li>
<li> Do not use in combination with other drugs that have demonstrated QT prolongation (<a href="#S4.1">4.1</a>)<br>Do not use in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to ziprasidone (<a href="#S4.2">4.2</a>)</li>
</ul>
<p>
 
</p>
<p></p>
<p>  Because of ziprasidone's dose-related prolongation of the QT interval and the known association of fatal <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> with QT prolongation by some other drugs, ziprasidone is contraindicated:</p>
<ul>
<li> in patients with a known history of QT prolongation (including congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>)</li>
<li> in patients with recent <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span></li>
<li> in patients with uncompensated <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span></li>
</ul>
<p>Pharmacokinetic/pharmacodynamic studies between ziprasidone and other drugs that prolong the QT interval have not been performed. An additive effect of ziprasidone and other drugs that prolong the QT interval cannot be excluded. Therefore, ziprasidone should not be given with:</p>
<ul>
<li> dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol or tacrolimus.</li>
<li> other drugs that have demonstrated QT prolongation as one of their pharmacodynamic effects and have this effect described in the full prescribing information as a contraindication or a boxed or bolded warning [<span class="Italics">see <a href="#S5.2">Warnings and Precautions (5.2)</a></span>].</li>
</ul>
<p>
 
</p>
<p></p>
<p>Ziprasidone is contraindicated in individuals with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the product.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>WARNINGS AND PRECAUTIONS</h1>
<p class="First"></p>
<ul>
<li>
<span class="Italics">QT Interval Prolongation</span>: GEODON use should be avoided in patients with <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, congenital prolongation of the QT interval, or in combination with other drugs that have demonstrated QT prolongation. (<a href="#S5.2">5.2</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> </span>(NMS): Potentially fatal symptom complex has been reported with antipsychotic drugs. Manage with immediate discontinuation of drug and close monitoring. (<a href="#S5.3">5.3</a>)</li>
<li>
<span class="Italics">Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms </span>(DRESS) has been reported with Ziprasidone exposure. DRESS is sometimes fatal. Discontinue Geodon if DRESS is suspected.(<a href="#S5.4">5.4</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span></span>: May develop acutely or chronically. (<a href="#S5.5">5.5</a>)</li>
<li>
<span class="Italics">Metabolic Changes</span>: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/ cerebrovascular risk. These metabolic changes include <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. (<a href="#S5.6">5.6</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus </span>(DM): Monitor all patients for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> including <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="438872" conceptname="Excessive eating - polyphagia">polyphagia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Patients with DM risk factors should undergo blood glucose testing before and during treatment. (<a href="#S5.6">5.6</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>: </span>Undesirable alterations have been observed in patients treated with atypical antipsychotics. (<a href="#S5.6">5.6</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span>:</span> <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> has been reported. Monitor <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. (<a href="#S5.6">5.6</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></span>: Discontinue in patients who develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> without an identified cause. (<a href="#S5.7">5.7</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></span>: Use with caution in patients with known cardiovascular or cerebrovascular disease. (<a href="#S5.8">5.8</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></span> has been reported with antipsychotics. Patients with a pre-existing low white blood cell count (WBC) or a history of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should have their complete blood count (CBC) monitored frequently during the first few months of therapy and should discontinue Geodon at the first sign of a decline in WBC in the absence of other causative factors. (<a href="#S5.9">5.9</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span>: Use cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or with conditions that lower <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold. (<a href="#S5.10">5.10</a>)</li>
<li>
<span class="Italics">Potential for Cognitive and Motor impairment</span>: Patients should use caution when operating machinery. (<a href="#S5.13">5.13</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span></span>: Closely supervise high-risk patients. (<a href="#S5.16">5.16</a>)</li>
</ul>
<p>
 
</p>
<p></p>
<p><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. GEODON is not approved for the treatment of <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. <span class="Italics">[see <a href="#BOX">Boxed Warning</a>]</span></span></p>
<p>
 
</p>
<p></p>
<p>Ziprasidone use should be avoided in combination with other drugs that are known to prolong the QTc interval [<span class="Italics">see <a href="#S4.1">Contraindications (4.1)</a>, <a href="#S7.4">Drug Interactions (7.4)</a>]</span>. Additionally, clinicians should be alert to the identification of other drugs that have been consistently observed to prolong the QTc interval. Such drugs should not be prescribed with ziprasidone. Ziprasidone should also be avoided in patients with congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span> and in patients with a history of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> <span class="Italics">[see <a href="#S4">Contraindications (4)</a>].</span></p>
<p>A study directly comparing the QT/QTc prolonging effect of oral ziprasidone with several other drugs effective in the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> was conducted in patient volunteers. In the first phase of the trial, ECGs were obtained at the time of maximum plasma concentration when the drug was administered alone. In the second phase of the trial, ECGs were obtained at the time of maximum plasma concentration while the drug was co-administered with an inhibitor of the CYP4503A4 metabolism of the drug.</p>
<p>In the first phase of the study, the mean change in QTc from baseline was calculated for each drug, using a sample-based correction that removes the effect of heart rate on the QT interval. The mean increase in QTc from baseline for ziprasidone ranged from approximately 9 to 14 msec greater than for four of the comparator drugs (risperidone, olanzapine, quetiapine, and haloperidol), but was approximately 14 msec less than the prolongation observed for thioridazine.</p>
<p>In the second phase of the study, the effect of ziprasidone on QTc length was not augmented by the presence of a metabolic inhibitor (ketoconazole 200 mg twice daily).</p>
<p>In placebo-controlled trials, oral ziprasidone increased the QTc interval compared to placebo by approximately 10 msec at the highest recommended daily dose of 160 mg. In clinical trials with oral ziprasidone, the electrocardiograms of 2/2988 (0.06%) patients who received GEODON and 1/440 (0.23%) patients who received placebo revealed QTc intervals exceeding the potentially clinically relevant threshold of 500 msec. In the ziprasidone-treated patients, neither case suggested a role of ziprasidone. One patient had a history of prolonged QTc and a screening measurement of 489 msec; QTc was 503 msec during ziprasidone treatment. The other patient had a QTc of 391 msec at the end of treatment with ziprasidone and upon switching to thioridazine experienced QTc measurements of 518 and 593 msec.</p>
<p>Some drugs that prolong the QT/QTc interval have been associated with the occurrence of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> and with sudden unexplained <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. The relationship of QT prolongation to <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> is clearest for larger increases (20 msec and greater) but it is possible that smaller QT/QTc prolongations may also increase risk, or increase it in susceptible individuals<span class="Bold">.</span> Although <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> has not been observed in association with the use of ziprasidone in premarketing studies and experience is too limited to rule out an increased risk, there have been rare post-marketing reports (in the presence of multiple confounding factors) <span class="Italics">[see <a href="#S6.2">Adverse Reactions (6.2)</a>]</span>.</p>
<p>A study evaluating the QT/QTc prolonging effect of intramuscular ziprasidone, with intramuscular haloperidol as a control, was conducted in patient volunteers. In the trial, ECGs were obtained at the time of maximum plasma concentration following two injections of ziprasidone (20 mg then 30 mg) or haloperidol (7.5 mg then 10 mg) given four hours apart. Note that a 30 mg dose of intramuscular ziprasidone is 50% higher than the recommended therapeutic dose. The mean change in QTc from baseline was calculated for each drug, using a sample-based correction that removes the effect of heart rate on the QT interval. The mean increase in QTc from baseline for ziprasidone was 4.6 msec following the first injection and 12.8 msec following the second injection. The mean increase in QTc from baseline for haloperidol was 6.0 msec following the first injection and 14.7 msec following the second injection. In this study, no patients had a QTc interval exceeding 500 msec.</p>
<p>As with other antipsychotic drugs and placebo, sudden unexplained <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have been reported in patients taking ziprasidone at recommended doses. The premarketing experience for ziprasidone did not reveal an excess risk of mortality for ziprasidone compared to other antipsychotic drugs or placebo, but the extent of exposure was limited, especially for the drugs used as active controls and placebo. Nevertheless, ziprasidone's larger prolongation of QTc length compared to several other antipsychotic drugs raises the possibility that the risk of <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> may be greater for ziprasidone than for other available drugs for treating <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. This possibility needs to be considered in deciding among alternative drug products <span class="Italics">[see <a href="#S1">Indications and Usage (1)</a>].</span></p>
<p>Certain circumstances may increase the risk of the occurrence of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> and/or <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> in association with the use of drugs that prolong the QTc interval, including (1) <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>; (2) <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval.</p>
<p>It is recommended that patients being considered for ziprasidone treatment who are at risk for significant <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> in particular, have baseline serum potassium and magnesium measurements. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> (and/or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>) may increase the risk of QT prolongation and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may result from diuretic therapy, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and other causes. Patients with low serum potassium and/or magnesium should be repleted with those electrolytes before proceeding with treatment. It is essential to periodically monitor serum electrolytes in patients for whom diuretic therapy is introduced during ziprasidone treatment. Persistently prolonged QTc intervals may also increase the risk of further prolongation and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, but it is not clear that routine screening ECG measures are effective in detecting such patients. Rather, ziprasidone should be avoided in patients with histories of significant cardiovascular illness, e.g., QT prolongation, recent <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, uncompensated <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>. Ziprasidone should be discontinued in patients who are found to have persistent QTc measurements &gt;500 msec.</p>
<p>For patients taking ziprasidone who experience symptoms that could indicate the occurrence of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>, e.g., <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, the prescriber should initiate further evaluation, e.g., Holter monitoring may be useful.</p>
<p>
 
</p>
<p></p>
<p>A potentially fatal symptom complex sometimes referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) has been reported in association with administration of antipsychotic drugs. Clinical manifestations of NMS are <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status, and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> (<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>), and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.</p>
<p>The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to exclude cases where the clinical presentation includes both serious medical illness (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, and primary central nervous system (CNS) pathology.</p>
<p>The management of NMS should include: (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for NMS.</p>
<p>If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported.</p>
<p>
 
</p>
<p></p>
<p><span>Drug reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and systemic symptoms (DRESS) has been reported with Ziprasidone exposure. DRESS consists of a combination of three or more of the following: cutaneous reaction (such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>), <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> and one or more systemic complications such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, and <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>. DRESS is sometimes fatal. Discontinue ziprasidone if DRESS is suspected.</span></p>
<p>
 
</p>
<p></p>
<p>A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients undergoing treatment with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> is unknown.</p>
<p>The risk of developing <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.</p>
<p>There is no known treatment for established cases of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome, and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.</p>
<p>Given these considerations, ziprasidone should be prescribed in a manner that is most likely to minimize the occurrence of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.</p>
<p>If signs and symptoms of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> appear in a patient on ziprasidone, drug discontinuation should be considered. However, some patients may require treatment with ziprasidone despite the presence of the syndrome.</p>
<p>
 
</p>
<p></p>
<p>Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, and body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</span></p>
<p><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, in some cases extreme and associated with <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span> or hyperosmolar <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been reported in patients treated with atypical antipsychotics. There have been few reports of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> in patients treated with GEODON. Although fewer patients have been treated with GEODON, it is not known if this more limited experience is the sole reason for the paucity of such reports. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and the increasing incidence of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse reactions is not completely understood. Precise risk estimates for <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse reactions in patients treated with atypical antipsychotics are not available.</p>
<p>Patients with an established diagnosis of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (e.g., <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, family history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> including <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="438872" conceptname="Excessive eating - polyphagia">polyphagia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Patients who develop symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug.</p>
<p>Pooled data from short-term, placebo-controlled studies in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar disorder are presented in Tables 1–4. Note that for the flexible dose studies in both <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar disorder, each subject is categorized as having received either low (20–40 mg BID) or high (60–80 mg BID) dose based on the subject's modal daily dose. In the tables showing categorical changes, the percentages (% column) are calculated as 100×(n/N).</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1: Glucose<a href="#footnote-1">*</a> Mean Change from Baseline in Short-Term (up to 6 weeks), Placebo-Controlled, Fixed-Dose, Oral Ziprasidone, Monotherapy Trials in Adult Patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></caption>
<col align="center" span="1" valign="middle" width="15%">
<col align="center" span="1" valign="middle" width="14%">
<col align="center" span="1" valign="middle" width="14%">
<col align="center" span="1" valign="middle" width="14%">
<col align="center" span="1" valign="middle" width="14%">
<col align="center" span="1" valign="middle" width="14%">
<col align="center" span="1" valign="middle" width="15%">
<tbody class="Headless">
<tr class="First"><th align="center" colspan="7">Mean Random Glucose Change from Baseline mg/dL (N)</th></tr>
<tr>
<th align="center" colspan="6">Ziprasidone</th>
<th align="center" colspan="1">Placebo</th>
</tr>
<tr>
<th align="center" colspan="1">5 mg BID</th>
<th align="center" colspan="1">20 mg BID</th>
<th align="center" colspan="1">40 mg BID</th>
<th align="center" colspan="1">60 mg BID</th>
<th align="center" colspan="1">80 mg BID</th>
<th align="center" colspan="1">100 mg BID</th>
</tr>
<tr class="Last">
<td align="center">-1.1 (N=45)</td>
<td align="center">+2.4 (N=179)</td>
<td align="center">-0.2 (N=146)</td>
<td align="center">-0.5 (N=119)</td>
<td align="center">-1.7 (N=104)</td>
<td align="center">+4.1 (N=85)</td>
<td align="center">+1.4 (N=260)</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a></p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2: Glucose<a href="#footnote-2">*</a> Categorical Changes in Short-Term (up to 6 weeks), Placebo-Controlled, Fixed-Dose, Oral Ziprasidone, Monotherapy Trials in Adult Patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></caption>
<col align="left" span="1" valign="top" width="16%">
<col align="left" span="1" valign="top" width="42%">
<col align="center" span="1" valign="top" width="16%">
<col align="center" span="1" valign="top" width="9%">
<col align="center" span="1" valign="top" width="17%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Laboratory Analyte</th>
<th align="left" colspan="1">Category Change (at least once) from Baseline</th>
<th align="center" colspan="1">Treatment Arm</th>
<th align="center" colspan="1">N</th>
<th align="center" colspan="1">n (%)</th>
</tr>
<tr>
<td align="left">Random Glucose</td>
<td align="left">Normal to High (&lt;100 mg/dL to ≥126 mg/dL)</td>
<td align="center">Ziprasidone</td>
<td align="center">438</td>
<td align="center">77 (17.6%)</td>
</tr>
<tr>
<td align="left">Placebo</td>
<td align="left">169</td>
<td align="center">26 (15.4%)</td>
</tr>
<tr>
<td align="left">Borderline to High (≥100 mg/dL and &lt;126 mg/dL to ≥126 mg/dL)</td>
<td align="left">Ziprasidone</td>
<td align="center">159</td>
<td align="center">54 (34.0%)</td>
</tr>
<tr class="Last">
<td align="left">Placebo</td>
<td align="left">66</td>
<td align="center">22 (33.3%)</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-2" href="#footnote-2" class="Sup">2</a></p>
<p>In long-term (at least 1 year), placebo-controlled, flexible-dose studies in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, the mean change from baseline in random glucose for ziprasidone 20–40 mg BID was -3.4 mg/dL (N=122); for ziprasidone 60–80 mg BID was +1.3 mg/dL (N=10); and for placebo was +0.3 mg/dL (N=71).</p>
<a name="t3"></a><table width="100%">
<caption><span>Table 3: Glucose<a href="#footnote-3">*</a> Mean Change from Baseline in Short-Term (up to 6 weeks), Placebo-Controlled, Flexible-Dose, Oral Ziprasidone, Monotherapy Trials in Adult Patients with Bipolar Disorder</span></caption>
<col align="center" span="1" valign="middle" width="40%">
<col align="center" span="1" valign="middle" width="40%">
<col align="center" span="1" valign="middle" width="20%">
<tbody class="Headless">
<tr class="First"><th align="center" colspan="3">Mean Fasting Glucose Change from Baseline mg/dL (N)</th></tr>
<tr>
<th align="center" colspan="2">Ziprasidone</th>
<th align="center" colspan="1">Placebo</th>
</tr>
<tr>
<th align="center" colspan="1">Low Dose: 20–40 mg BID</th>
<th align="center" colspan="1">High Dose: 60–80 mg BID</th>
</tr>
<tr class="Last">
<td align="center">+0.1 (N=206)</td>
<td align="center">+1.6 (N=166)</td>
<td align="center">+1.4 (N=287)</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-3" href="#footnote-3" class="Sup">3</a></p>
<a name="t4"></a><table width="100%">
<caption><span>Table 4: Glucose<a href="#footnote-4">*</a> Categorical Changes in Short-Term (up to 6 weeks), Placebo-Controlled, Flexible-Dose, Oral Ziprasidone, Monotherapy Trials in Adult Patients with Bipolar Disorder</span></caption>
<col align="left" span="1" valign="top" width="16%">
<col align="left" span="1" valign="top" width="42%">
<col align="center" span="1" valign="top" width="16%">
<col align="center" span="1" valign="top" width="9%">
<col align="center" span="1" valign="top" width="17%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Laboratory Analyte</th>
<th align="left" colspan="1">Category Change (at least once) from Baseline</th>
<th align="center" colspan="1">Treatment Arm</th>
<th align="center" colspan="1">N </th>
<th align="center" colspan="1">n (%)    </th>
</tr>
<tr>
<td align="left">Fasting Glucose</td>
<td align="left">Normal to High (&lt;100 mg/dL to ≥126 mg/dL)</td>
<td align="center">Ziprasidone</td>
<td align="center">  272</td>
<td align="center">5 (1.8%)</td>
</tr>
<tr>
<td align="left">Placebo</td>
<td align="left">  210</td>
<td align="center">2 (1.0%)</td>
</tr>
<tr>
<td align="left">Borderline to High (≥100 mg/dL and &lt;126 mg/dL to ≥126 mg/dL)</td>
<td align="left">Ziprasidone</td>
<td align="center">79</td>
<td align="center">    12 (15.2%)</td>
</tr>
<tr class="Last">
<td align="left">Placebo</td>
<td align="left">71</td>
<td align="center">7 (9.9%)</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-4" href="#footnote-4" class="Sup">4</a></p>
<p>
 
</p>
<p></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></span></p>
<p>Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics. Pooled data from short-term, placebo-controlled studies in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar disorder are presented in Tables 5–8.</p>
<a name="t5"></a><table width="100%">
<caption><span>Table 5: Lipid<a href="#footnote-1">*</a> Mean Change from Baseline in Short-Term (up to 6 weeks), Placebo-Controlled, Fixed-Dose, Oral Ziprasidone Monotherapy Trials in Adult Patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> </span></caption>
<col align="left" span="1" valign="top" width="14%">
<col align="center" span="1" valign="top" width="12%">
<col align="center" span="1" valign="top" width="12%">
<col align="center" span="1" valign="top" width="12%">
<col align="center" span="1" valign="top" width="12%">
<col align="center" span="1" valign="top" width="12%">
<col align="center" span="1" valign="top" width="12%">
<col align="center" span="1" valign="top" width="14%">
<tbody class="Headless">
<tr class="First"><th align="left" colspan="8">Mean Lipid Change from Baseline mg/dL (N)</th></tr>
<tr>
<th align="left" colspan="1">Laboratory Analyte</th>
<th align="center" colspan="6">Ziprasidone</th>
<th align="center" colspan="1">Placebo</th>
</tr>
<tr>
<th align="left" colspan="1">5 mg BID</th>
<th align="center" colspan="1">20 mg BID</th>
<th align="center" colspan="1">40 mg BID</th>
<th align="center" colspan="1">60 mg BID</th>
<th align="center" colspan="1">80 mg BID</th>
<th align="center" colspan="1">100 mg BID</th>
</tr>
<tr>
<td align="left">Triglycerides</td>
<td align="center">-12.9 (N=45)</td>
<td align="center">-9.6 (N=181)</td>
<td align="center">-17.3 (N=146)</td>
<td align="center">-0.05 (N=120)</td>
<td align="center">-16.0 (N=104)</td>
<td align="center">+0.8 (N=85)</td>
<td align="center">-18.6 (N=260)</td>
</tr>
<tr class="Last">
<td align="left">Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td align="center">-3.6 (N=45)</td>
<td align="center">-4.4 (N=181)</td>
<td align="center">-8.2 (N=147)</td>
<td align="center">-3.6 (N=120)</td>
<td align="center">-10.0 (N=104)</td>
<td align="center">-3.6 (N=85)</td>
<td align="center">-4.7 (N=261)</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-5" href="#footnote-5" class="Sup">5</a></p>
<a name="t6"></a><table width="100%">
<caption><span>Table 6: Lipid<a href="#footnote-2">*</a> Categorical Changes in Short-Term (up to 6 weeks), Placebo-Controlled, Fixed-Dose, Oral Ziprasidone Monotherapy Trials in Adult Patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></caption>
<col align="left" span="1" valign="top" width="16%">
<col align="left" span="1" valign="top" width="42%">
<col align="center" span="1" valign="top" width="16%">
<col align="center" span="1" valign="top" width="9%">
<col align="center" span="1" valign="top" width="17%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Laboratory Analyte</th>
<th align="left" colspan="1">Category Change (at least once) from Baseline</th>
<th align="center" colspan="1">Treatment Arm</th>
<th align="center" colspan="1">N</th>
<th align="center" colspan="1">n (%)</th>
</tr>
<tr>
<td align="left">Triglycerides</td>
<td align="left">Increase by ≥50 mg/dL</td>
<td align="center">Ziprasidone</td>
<td align="center">681</td>
<td align="center">232 (34.1%)</td>
</tr>
<tr>
<td align="left">Placebo</td>
<td align="left">260</td>
<td align="center">53 (20.4%)</td>
</tr>
<tr>
<td align="left">Normal to High (&lt;150 mg/dL to ≥200 mg/dL)</td>
<td align="left">Ziprasidone</td>
<td align="center">429</td>
<td align="center">63 (14.7%)</td>
</tr>
<tr>
<td align="left">Placebo</td>
<td align="left">152</td>
<td align="center">12 (7.9%)</td>
</tr>
<tr>
<td align="left">Borderline to High (≥150 mg/dL and &lt;200 mg/dL to ≥200 mg/dL)</td>
<td align="left">Ziprasidone</td>
<td align="center">92</td>
<td align="center">43 (46.7%)</td>
</tr>
<tr>
<td align="left">Placebo</td>
<td align="left">41</td>
<td align="center">12 (29.3%)</td>
</tr>
<tr>
<td align="left">Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td align="left">Increase by ≥40 mg/dL</td>
<td align="center">Ziprasidone</td>
<td align="center">682</td>
<td align="center">76 (11.1%)</td>
</tr>
<tr>
<td align="left">Placebo</td>
<td align="left">261</td>
<td align="center">26 (10.0%)</td>
</tr>
<tr>
<td align="left">Normal to High (&lt;200 mg/dL to ≥240 mg/dL)</td>
<td align="left">Ziprasidone</td>
<td align="center">380</td>
<td align="center">15 (3.9%)</td>
</tr>
<tr>
<td align="left">Placebo</td>
<td align="left">145</td>
<td align="center">0 (0.0%)</td>
</tr>
<tr>
<td align="left">Borderline to High (≥200 mg/dL and &lt;240 mg/dL to ≥240 mg/dL)</td>
<td align="left">Ziprasidone</td>
<td align="center">207</td>
<td align="center">56 (27.1%)</td>
</tr>
<tr class="Last">
<td align="left">Placebo</td>
<td align="left">82</td>
<td align="center">22 (26.8%)</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-6" href="#footnote-6" class="Sup">6</a></p>
<p>In long-term (at least 1 year), placebo-controlled, flexible-dose studies in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, the mean change from baseline in random triglycerides for ziprasidone 20–40 mg BID was +26.3 mg/dL (N=15); for ziprasidone 60–80 mg BID was -39.3 mg/dL (N=10); and for placebo was +12.9 mg/dL (N=9). In long-term (at least 1 year), placebo-controlled, flexible-dose studies in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, the mean change from baseline in random total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> for ziprasidone 20–40 mg BID was +2.5 mg/dL (N=14); for ziprasidone 60–80 mg BID was -19.7 mg/dL (N=10); and for placebo was -28.0 mg/dL (N=9).</p>
<a name="t7"></a><table width="100%">
<caption><span>Table 7: Lipid<a href="#footnote-3">*</a> Mean Change from Baseline in Short-Term (up to 6 weeks), Placebo-Controlled, Flexible-Dose, Oral Ziprasidone Monotherapy Trials in Adult Patients with Bipolar Disorder</span></caption>
<col align="left" span="1" valign="top" width="25%">
<col align="center" span="1" valign="top" width="30%">
<col align="center" span="1" valign="top" width="30%">
<col align="center" span="1" valign="top" width="15%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Laboratory Analyte</th>
<th align="center" colspan="3">Mean Change from Baseline mg/dL (N)</th>
</tr>
<tr>
<th align="left" colspan="2">Ziprasidone</th>
<th align="center" colspan="1">Placebo</th>
</tr>
<tr>
<th align="left" colspan="1">Low Dose: 20–40 mg BID</th>
<th align="center" colspan="1">High Dose: 60–80 mg BID</th>
</tr>
<tr>
<td align="left">Fasting Triglycerides</td>
<td align="center">+0.95 (N=206)</td>
<td align="center">-3.5 (N=165)</td>
<td align="center">+8.6 (N=286)</td>
</tr>
<tr>
<td align="left">Fasting Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td align="center">-2.8 (N=206)</td>
<td align="center">-3.4 (N=165)</td>
<td align="center">-1.6 (N=286)</td>
</tr>
<tr>
<td align="left">Fasting LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td align="center">-3.0 (N=201)</td>
<td align="center">-3.1 (N=158)</td>
<td align="center">-1.97 (N=270)</td>
</tr>
<tr class="Last">
<td align="left">Fasting HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span></td>
<td align="center">-0.09 (N=206)</td>
<td align="center">+0.3 (N=165)</td>
<td align="center">-0.9 (N=286)</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-7" href="#footnote-7" class="Sup">7</a></p>
<a name="t8"></a><table width="100%">
<caption><span>Table 8: Lipid<a href="#footnote-4">*</a> Categorical Changes in Short-Term (up to 6 weeks), Placebo-Controlled, Flexible-Dose, Oral Ziprasidone Monotherapy Trials in Adult Patients with Bipolar Disorder</span></caption>
<col align="left" span="1" valign="top" width="16%">
<col align="left" span="1" valign="top" width="42%">
<col align="left" span="1" valign="top" width="16%">
<col align="center" span="1" valign="top" width="9%">
<col align="center" span="1" valign="top" width="17%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Laboratory Analyte</th>
<th align="left" colspan="1">Category Change (at least once) from Baseline</th>
<th align="left" colspan="1">Treatment Arm</th>
<th align="center" colspan="1">N</th>
<th align="center" colspan="1">n (%)</th>
</tr>
<tr>
<td align="left">Fasting Triglycerides</td>
<td align="left">Increase by ≥50 mg/dL</td>
<td align="left">Ziprasidone</td>
<td align="center">371</td>
<td align="center">66 (17.8%)</td>
</tr>
<tr>
<td align="left">Placebo</td>
<td align="left">286</td>
<td align="left">62 (21.7%)</td>
</tr>
<tr>
<td align="left">Normal to High (&lt;150 mg/dL to ≥200 mg/dL)</td>
<td align="left">Ziprasidone</td>
<td align="left">225</td>
<td align="center">15 (6.7%)</td>
</tr>
<tr>
<td align="left">Placebo</td>
<td align="left">179</td>
<td align="left">13 (7.3%)</td>
</tr>
<tr>
<td align="left">Borderline to High (≥150 mg/dL and &lt;200 mg/dL to ≥200 mg/dL)</td>
<td align="left">Ziprasidone</td>
<td align="left">58</td>
<td align="center">16 (27.6%)</td>
</tr>
<tr>
<td align="left">Placebo</td>
<td align="left">47</td>
<td align="left">14 (29.8%)</td>
</tr>
<tr>
<td align="left">Fasting Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td align="left">Increase by ≥40 mg/dL</td>
<td align="left">Ziprasidone</td>
<td align="center">371</td>
<td align="center">30 (8.1%)</td>
</tr>
<tr>
<td align="left">Placebo</td>
<td align="left">286</td>
<td align="left">13 (4.5%)</td>
</tr>
<tr>
<td align="left">Normal to High (&lt;200 mg/dL to ≥240 mg/dL)</td>
<td align="left">Ziprasidone</td>
<td align="left">204</td>
<td align="center">5 (2.5%)</td>
</tr>
<tr>
<td align="left">Placebo</td>
<td align="left">151</td>
<td align="left">2 (1.3%)</td>
</tr>
<tr>
<td align="left">Borderline to High (≥200 mg/dL and &lt;240 mg/dL to ≥240 mg/dL)</td>
<td align="left">Ziprasidone</td>
<td align="left">106</td>
<td align="center">10 (9.4%)</td>
</tr>
<tr>
<td align="left">Placebo</td>
<td align="left">87</td>
<td align="left">15 (17.2%)</td>
</tr>
<tr>
<td align="left">Fasting LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td align="left">Increase by ≥30 mg/dL</td>
<td align="left">Ziprasidone</td>
<td align="center">359</td>
<td align="center">39 (10.9%)</td>
</tr>
<tr>
<td align="left">Placebo</td>
<td align="left">270</td>
<td align="left">17 (6.3%)</td>
</tr>
<tr>
<td align="left">Normal to High (&lt;100 mg/dL to ≥160 mg/dL)</td>
<td align="left">Ziprasidone</td>
<td align="left">115</td>
<td align="center">0 (0%)</td>
</tr>
<tr>
<td align="left">Placebo</td>
<td align="left">89</td>
<td align="left">1 (1.1%)</td>
</tr>
<tr>
<td align="left">Borderline to High (≥100 mg/dL and &lt;160 mg/dL to ≥160 mg/dL)</td>
<td align="left">Ziprasidone</td>
<td align="left">193</td>
<td align="center">18 (9.3%)</td>
</tr>
<tr>
<td align="left">Placebo</td>
<td align="left">141</td>
<td align="left">14 (9.9%)</td>
</tr>
<tr>
<td align="left">Fasting HDL</td>
<td align="left">Normal (&gt;=40 mg/dL) to Low (&lt;40 mg/dL)</td>
<td align="left">Ziprasidone</td>
<td align="center">283</td>
<td align="center">22 (7.8%)</td>
</tr>
<tr class="Last">
<td align="left">Placebo</td>
<td align="left">220</td>
<td align="left">24 (10.9%)</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-8" href="#footnote-8" class="Sup">8</a></p>
<p>
 
</p>
<p></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> has been observed with atypical antipsychotic use. Monitoring of weight is recommended. Pooled data from short-term, placebo-controlled studies in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar disorder are presented in Tables 9–10.</p>
<a name="t9"></a><table width="100%">
<caption><span>Table 9: Weight Mean Changes in Short-Term (up to 6 weeks), Placebo-Controlled, Fixed-Dose, Oral Ziprasidone Monotherapy Trials in Adult Patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></caption>
<col align="center" span="1" valign="top" width="14%">
<col align="center" span="1" valign="top" width="14%">
<col align="center" span="1" valign="top" width="14%">
<col align="center" span="1" valign="top" width="14%">
<col align="center" span="1" valign="top" width="14%">
<col align="center" span="1" valign="top" width="14%">
<col align="center" span="1" valign="top" width="16%">
<tbody class="Headless">
<tr class="First">
<th align="center" colspan="6">Ziprasidone</th>
<th align="center" colspan="1">Placebo</th>
</tr>
<tr>
<th align="center" colspan="1">5 mg BID</th>
<th align="center" colspan="1">20 mg BID</th>
<th align="center" colspan="1">40 mg BID</th>
<th align="center" colspan="1">60 mg BID</th>
<th align="center" colspan="1">80 mg BID</th>
<th align="center" colspan="1">100 mg BID</th>
</tr>
<tr><td align="center"><span class="Bold">Mean Weight (kg) Changes from Baseline (N)</span></td></tr>
<tr>
<td align="center">+0.3 (N=40)</td>
<td align="center">+1.0 (N=167)</td>
<td align="center">+1.0 (N=135)</td>
<td align="center">+0.7 (N=109)</td>
<td align="center">+1.1 (N=97)</td>
<td align="center">+0.9 (N=74)</td>
<td align="center">-0.4 (227)</td>
</tr>
<tr><td align="center"><span class="Bold">Proportion of Patients with ≥7% Increase in Weight from Baseline (N)</span></td></tr>
<tr class="Last">
<td align="center">0.0% (N=40)</td>
<td align="center">9.0% (N=167)</td>
<td align="center">10.4% (N=135)</td>
<td align="center">7.3% (N=109)</td>
<td align="center">15.5% (N=97)</td>
<td align="center">10.8% (N=74)</td>
<td align="center">4.0% (N=227)</td>
</tr>
</tbody>
</table>
<p>In long-term (at least 1 year), placebo-controlled, flexible-dose studies in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, the mean change from baseline weight for ziprasidone 20–40 mg BID was -2.3 kg (N=124); for ziprasidone 60–80 mg BID was +2.5 kg (N=10); and for placebo was -2.9 kg (N=72). In the same long-term studies, the proportion of subjects with <span class="Bold">≥ </span>7% increase in weight from baseline for ziprasidone 20–40 mg BID was 5.6% (N=124); for ziprasidone 60–80 mg BID was 20.0% (N=10), and for placebo was 5.6% (N=72). In a long-term (at least 1 year), placebo-controlled, fixed-dose study in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, the mean change from baseline weight for ziprasidone 20 mg BID was -2.6 kg (N=72); for ziprasidone 40 mg BID was -3.3 kg (N=69); for ziprasidone 80 mg BID was -2.8 kg (N=70) and for placebo was -3.8 kg (N=70). In the same long-term fixed-dose <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> study, the proportion of subjects with <span class="Bold">≥ </span>7% increase in weight from baseline for ziprasidone 20 mg BID was 5.6% (N=72); for ziprasidone 40 mg BID was 2.9% (N=69); for ziprasidone 80 mg BID was 5.7% (N=70) and for placebo was 2.9% (N=70).</p>
<a name="t10"></a><table width="100%">
<caption><span>Table 10: Summary of Weight Change in Short-Term (up to 6 weeks), Placebo-Controlled, Flexible-Dose, Oral Ziprasidone Monotherapy Trials in Adult Patients with Bipolar Disorder:</span></caption>
<col align="center" span="1" valign="middle" width="40%">
<col align="center" span="1" valign="middle" width="40%">
<col align="center" span="1" valign="middle" width="20%">
<tbody class="Headless">
<tr class="First">
<th align="center" colspan="2">Ziprasidone</th>
<th align="center" colspan="1">Placebo</th>
</tr>
<tr>
<th align="center" colspan="1">Low Dose: 20–40 mg BID</th>
<th align="center" colspan="1">High Dose<a href="#footnote-1">*</a>: 60–80 mg BID</th>
</tr>
<tr><td align="center"><span class="Bold">Mean Weight (kg) Changes from Baseline (N)</span></td></tr>
<tr>
<td align="center">+0.4 (N=295)</td>
<td align="center">+0.4 (N=388)</td>
<td align="center">+0.1 (N=451)</td>
</tr>
<tr><td align="center"><span class="Bold">Proportion of Patients with ≥ 7% Increase in Weight from Baseline (N)</span></td></tr>
<tr class="Last">
<td align="center">2.4% (N=295)</td>
<td align="center">4.4% (N=388)</td>
<td align="center">1.8% (N=451)</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-9" href="#footnote-9" class="Sup">9</a></p>
<p>
 
</p>
<p></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> </span>- The proportions of patients meeting a <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> criterion of ≥ 7% of body weight were compared in a pool of four 4- and 6-week placebo-controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> clinical trials, revealing a statistically significantly greater incidence of <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> for ziprasidone (10%) compared to placebo (4%). A median <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> of 0.5 kg was observed in ziprasidone patients compared to no median weight change in placebo patients. In this set of clinical trials, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was reported as an adverse reaction in 0.4% and 0.4% of ziprasidone and placebo patients, respectively. During long-term therapy with ziprasidone, a categorization of patients at baseline on the basis of body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI) revealed the greatest mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and highest incidence of clinically significant <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> (&gt; 7% of body weight) in patients with low BMI (&lt;23) compared to normal (23–27) or overweight patients (&gt;27). There was a mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> of 1.4 kg for those patients with a "low" baseline BMI, no mean change for patients with a "normal" BMI, and a 1.3 kg mean <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> for patients who entered the program with a "high" BMI.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Bipolar Disorder</span> – During a 6-month placebo-controlled bipolar maintenance study in adults with ziprasidone as an adjunct to lithium or valproate, the incidence of clinically significant <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> (≥ 7% of body weight) during the double-blind period was 5.6% for both ziprasidone and placebo treatment groups who completed the 6 months of observation for relapse. Interpretation of these findings should take into consideration that only patients who adequately tolerated ziprasidone entered the double-blind phase of the study, and there were substantial dropouts during the open label phase.</p>
<p>
 
</p>
<p></p>
<p>In premarketing trials with ziprasidone, about 5% of patients developed <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and/or <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, with discontinuation of treatment in about one-sixth of these cases. The occurrence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> was related to dose of ziprasidone, although the finding might also be explained by the longer exposure time in the higher dose patients. Several patients with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> had signs and symptoms of associated systemic illness, e.g., elevated WBCs. Most patients improved promptly with adjunctive treatment with antihistamines or steroids and/or upon discontinuation of ziprasidone, and all patients experiencing these reactions were reported to recover completely. Upon appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> for which an alternative etiology cannot be identified, ziprasidone should be discontinued.</p>
<p>
 
</p>
<p></p>
<p>Ziprasidone may induce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> associated with <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and, in some patients, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, especially during the initial dose-titration period, probably reflecting its α<span class="Sub">1</span>-adrenergic antagonist properties. <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> was reported in 0.6% of the patients treated with ziprasidone.</p>
<p>Ziprasidone should be used with particular caution in patients with known cardiovascular disease (history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (<span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, and treatment with antihypertensive medications).</p>
<p>
 
</p>
<p></p>
<p>In clinical trial and postmarketing experience, events of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> have been reported temporally related to antipsychotic agents. <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> (including fatal cases) has also been reported.</p>
<p>Possible risk factors for <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> include pre-existing low white blood cell count (WBC) and history of drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. Patients with a pre-existing low WBC or a history of drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should have their complete blood count (CBC) monitored frequently during the first few months of therapy and should discontinue Geodon at the first sign of decline in WBC in the absence of other causative factors.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should be carefully monitored for <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other symptoms or signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and treated promptly if such symptoms or signs occur. Patients with severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (absolute neutrophil count &lt;1000/mm3) should discontinue Geodon and have their WBC followed until recovery.</p>
<p>
 
</p>
<p></p>
<p>During clinical trials, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> occurred in 0.4% of patients treated with ziprasidone. There were confounding factors that may have contributed to the occurrence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in many of these cases. As with other antipsychotic drugs, ziprasidone should be used cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or with conditions that potentially lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold, e.g., Alzheimer's <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. Conditions that lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold may be more prevalent in a population of 65 years or older.</p>
<p>
 
</p>
<p></p>
<p>Esophageal dysmotility and <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> have been associated with antipsychotic drug use. <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">Aspiration pneumonia</span> is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. Ziprasidone and other antipsychotic drugs should be used cautiously in patients at risk for <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">aspiration pneumonia</span> <span class="Italics">[see <a href="#BOX">Boxed Warning</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p>As with other drugs that antagonize dopamine D<span class="Sub">2</span> receptors, ziprasidone elevates prolactin levels in humans. Increased prolactin levels were also observed in animal studies with this compound, and were associated with an increase in mammary gland neoplasia in mice; a similar effect was not observed in rats <span class="Italics">[see <a href="#S13.1">Nonclinical Toxicology (13.1)</a>]</span>. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent <span class="Italics">in vitro</span>, a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected breast cancer. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans; the available evidence is considered too limited to be conclusive at this time.</p>
<p>Although disturbances such as <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> have been reported with prolactin-elevating compounds, the clinical significance of elevated serum prolactin levels is unknown for most patients. Long-standing <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">hyperprolactinemia</span> when associated with <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> may lead to decreased bone density.</p>
<p>
 
</p>
<p></p>
<p><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> was a commonly reported adverse reaction in patients treated with ziprasidone. In the 4- and 6-week placebo-controlled trials, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> was reported in 14% of patients on ziprasidone compared to 7% of placebo patients. <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> led to discontinuation in 0.3% of patients in short-term clinical trials. Since ziprasidone has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about performing activities requiring mental alertness, such as operating a motor vehicle (including automobiles) or operating hazardous machinery until they are reasonably certain that ziprasidone therapy does not affect them adversely.</p>
<p>
 
</p>
<p></p>
<p>One case of <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span> was reported in the premarketing database. While the relationship of the reaction to ziprasidone use has not been established, other drugs with alpha-adrenergic blocking effects have been reported to induce <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>, and it is possible that ziprasidone may share this capacity. Severe <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span> may require <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>.</p>
<p>
 
</p>
<p></p>
<p>Although not reported with ziprasidone in premarketing trials, disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing ziprasidone for patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>.</p>
<p>
 
</p>
<p></p>
<p>The possibility of a <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> is inherent in <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> illness or bipolar disorder, and close supervision of high-risk patients should accompany drug therapy. Prescriptions for ziprasidone should be written for the smallest quantity of capsules consistent with good patient management in order to reduce the risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
<p>
 
</p>
<p></p>
<p>Clinical experience with ziprasidone in patients with certain concomitant systemic illnesses is limited <span class="Italics">[see <a href="#S8.6">Use in Specific Populations (8.6)</a>,<a href="#S8.7">( 8.7)</a>].</span></p>
<p>Ziprasidone has not been evaluated or used to any appreciable extent in patients with a recent history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or unstable heart disease. Patients with these diagnoses were excluded from premarketing clinical studies. Because of the risk of QTc prolongation and <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> with ziprasidone, caution should be observed in cardiac patients. <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>, <a href="#S5.8">(5.8)</a>].</span></p>
<p>
 
</p>
<p></p>
<p>Patients being considered for ziprasidone treatment that are at risk of significant <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span> should have baseline serum potassium and magnesium measurements. Low serum potassium and magnesium should be replaced before proceeding with treatment. Patients who are started on diuretics during Ziprasidone therapy need periodic monitoring of serum potassium and magnesium. Ziprasidone should be discontinued in patients who are found to have persistent QTc measurements &gt;500 msec <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>].</span></p>
<p>
 
</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>"Random" glucose measurements—fasting/non-fasting status unknown</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">2</a></dt>
<dd>"Random" glucose measurements – fasting/non-fasting status unknown</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">3</a></dt>
<dd>Fasting</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">4</a></dt>
<dd>Fasting</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">5</a></dt>
<dd>Random" lipid measurements, fasting/non-fasting status unknown</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">6</a></dt>
<dd>Random" lipid measurements, fasting/non-fasting status unknown</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">7</a></dt>
<dd>Fasting</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">8</a></dt>
<dd>Fasting</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">9</a></dt>
<dd>Note that in the High Dose group, there were 2 subjects with modal 200 mg total daily dose and 1 subject with modal 100 mg total daily dose.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"></p>
<p>Commonly observed adverse reactions (incidence ≥5% and at least twice the incidence for placebo) were<span class="Bold">:</span></p>
<ul>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span>: <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>, <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infection</span>. (<a href="#S6.1">6.1</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> and Mixed Episodes Associated with Bipolar Disorder</span>: <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. (<a href="#S6.1">6.1</a>)</li>
<li>
<span class="Italics">Intramuscular administration </span>(≥5% and at least twice the lowest intramuscular ziprasidone group): <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. (<a href="#S6.1">6.1</a>)</li>
</ul>
<p><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span></p>
<p>
 
</p>
<p></p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>Clinical trials for oral ziprasidone included approximately 5700 patients and/or normal subjects exposed to one or more doses of ziprasidone. Of these 5700, over 4800 were patients who participated in multiple-dose effectiveness trials, and their experience corresponded to approximately 1831 patient-years. These patients include: (1) 4331 patients who participated in multiple-dose trials, predominantly in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, representing approximately 1698 patient-years of exposure as of February 5, 2000; and (2) 472 patients who participated in bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials representing approximately 133 patient-years of exposure. An additional 127 patients with bipolar disorder participated in a long-term maintenance treatment study representing approximately 74.7 patient-years of exposure to ziprasidone. The conditions and duration of treatment with ziprasidone included open-label and double-blind studies, inpatient and outpatient studies, and short-term and longer-term exposure.</p>
<p>Clinical trials for intramuscular ziprasidone included 570 patients and/or normal subjects who received one or more injections of ziprasidone. Over 325 of these subjects participated in trials involving the administration of multiple doses.</p>
<p>Adverse reactions during exposure were obtained by collecting voluntarily reported adverse experiences, as well as results of physical examinations, vital signs, weights, laboratory analyses, ECGs, and results of ophthalmologic examinations.</p>
<p>The stated frequencies of adverse reactions represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse reaction of the type listed. A reaction was considered treatment emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Adverse Findings Observed in Short-Term, Placebo-Controlled Trials with Oral Ziprasidone</span></p>
<p>The following findings are based on the short-term placebo-controlled premarketing trials for <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (a pool of two 6-week, and two 4-week fixed-dose trials) and bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> (a pool of two 3-week flexible-dose trials) in which ziprasidone was administered in doses ranging from 10 to 200 mg/day.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Commonly Observed Adverse Reactions in Short Term-Placebo-Controlled Trials </span></p>
<p>The following adverse reactions were the most commonly observed adverse reactions associated with the use of ziprasidone (incidence of 5% or greater) and not observed at an equivalent incidence among placebo-treated patients (ziprasidone incidence at least twice that for placebo):</p>
<p><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> trials <span class="Italics">(see <a href="#table11">Table 11</a>)</span></p>
<ul>
<li>   <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></li>
<li>   <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory Tract Infection</span></li>
</ul>
<p>Bipolar trials <span class="Italics">(see <a href="#table12">Table 12</a>)</span></p>
<ul>
<li>   <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></li>
<li>   <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span> which includes the following adverse reaction terms: <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal syndrome</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> and <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>. None of these adverse reactions occurred individually at an incidence greater than 10% in bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials.</li>
<li>   <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> which includes the adverse reaction terms <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>.</li>
<li>   <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span></li>
<li>   <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal Vision</span></li>
<li>   <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></li>
<li>   <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></li>
</ul>
<p>
 
</p>
<p></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">SCHIZOPHRENIA</span> </span></p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Adverse Reactions Associated with Discontinuation of Treatment in Short-Term, Placebo-Controlled Trials of Oral Ziprasidone </span></p>
<p>Approximately 4.1% (29/702) of ziprasidone-treated patients in short-term, placebo-controlled studies discontinued treatment due to an adverse reaction, compared with about 2.2% (6/273) on placebo. The most common reaction associated with dropout was <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, including 7 dropouts for <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> among ziprasidone patients (1%) compared to no placebo patients <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>].</span></p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Adverse Reactions Occurring at an Incidence of 2% or More Among Ziprasidone-Treated Patients in Short-Term, Oral, Placebo-Controlled Trials </span></p>
<p>Table 11 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred during acute therapy (up to 6 weeks) in predominantly patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, including only those reactions that occurred in 2% or more of patients treated with ziprasidone and for which the incidence in patients treated with ziprasidone was greater than the incidence in placebo-treated patients.</p>
<a name="table11"></a><table width="80%">
<caption><span>Table 11: Treatment-Emergent Adverse Reaction Incidence In Short-Term Oral Placebo-Controlled Trials – <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></caption>
<col align="left" span="1" valign="top" width="40%">
<col align="center" span="1" valign="top" width="30%">
<col align="center" span="1" valign="top" width="30%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1"></th>
<th align="center" colspan="2">Percentage of Patients<br> Reporting Reaction</th>
</tr>
<tr>
<th align="left" colspan="1">Body System/Adverse Reaction</th>
<th align="center" colspan="1">Ziprasidone<br> (N=702)</th>
<th align="center" colspan="1">Placebo<br> (N=273)</th>
</tr>
<tr>
<td align="left"><span class="Bold">Body as a Whole</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center">5</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental Injury</span></td>
<td align="center">4</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></td>
<td align="center">3</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left"><span class="Bold">Cardiovascular</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="Bold">Digestive</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">10</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center">9</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center">8</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">5</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></td>
<td align="center">4</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="Bold">Nervous</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span><a href="#footnote-1">*</a>
</td>
<td align="center">14</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center">14</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span></td>
<td align="center">8</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span><a href="#footnote-2">†</a>
</td>
<td align="center">8</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left"><span class="Bold">Respiratory</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory Tract Infection</span></td>
<td align="center">8</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td align="center">4</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough Increased</span></td>
<td align="center">3</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="Bold">Skin and Appendages</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center">4</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="137213" conceptname="Dermal mycosis">Fungal Dermatitis</span></td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="Bold">Special Senses</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td align="left">  <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal Vision</span></td>
<td align="center">3</td>
<td align="center">2</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-10" href="#footnote-10" class="Sup">10</a></p>
<p><a name="footnote-reference-11" href="#footnote-11" class="Sup">11</a></p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Dose Dependency of Adverse Reactions in Short-Term, Fixed-Dose, Placebo-Controlled Trials</span></p>
<p>An analysis for dose response in the <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> 4-study pool revealed an apparent relation of adverse reaction to dose for the following reactions: <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">increased salivation</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span><span class="Italics">.</span></p>
<p>
 
</p>
<p></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span> (EPS) </span>- The incidence of reported EPS (which included the adverse reaction terms <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal syndrome</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> and <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>) for ziprasidone-treated patients in the short-term, placebo-controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trials was 14% vs. 8% for placebo. Objectively collected data from those trials on the Simpson-Angus Rating Scale (for EPS) and the Barnes <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> Scale (for <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>) did not generally show a difference between ziprasidone and placebo.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span></span><span class="Italics"> - Class Effect:</span> Symptoms of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">acute dystonia</span> is observed in males and younger age groups.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Vital Sign Changes</span> - Ziprasidone is associated with <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> [<span class="Italics">see <a href="#S5.8">Warnings and Precautions (5.8)</a></span>]</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">ECG Changes - </span>Ziprasidone is associated with an increase in the QTc interval <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>. In the <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trials, ziprasidone was associated with a mean increase in heart rate of 1.4 beats per minute compared to a 0.2 beats per minute decrease among placebo patients.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Other Adverse Reactions Observed During the Premarketing Evaluation of Oral Ziprasidone</span></p>
<p>Following is a list of COSTART terms that reflect treatment-emergent adverse reactions as defined in the introduction to the <span class="Bold">ADVERSE REACTIONS</span> section reported by patients treated with ziprasidone in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trials at multiple doses &gt;4 mg/day within the database of 3834 patients. All reported reactions are included except those already listed in Table 11 or elsewhere in labeling, those reaction terms that were so general as to be uninformative, reactions reported only once and that did not have a substantial probability of being acutely life-threatening, reactions that are part of the illness being treated or are otherwise common as background reactions, and reactions considered unlikely to be drug-related. It is important to emphasize that, although the reactions reported occurred during treatment with ziprasidone, they were not necessarily caused by it.</p>
<p>Adverse reactions are further categorized by body system and listed in order of decreasing frequency according to the following definitions:</p>
<p><span class="Italics">Frequent - </span>adverse reactions occurring in at least 1/100 patients (≥1.0% of patients) (only those not already listed in the tabulated results from placebo-controlled trials appear in this listing);</p>
<p><span class="Italics">Infrequent - </span>adverse reactions occurring in 1/100 to 1/1000 patients (in 0.1–1.0% of patients)</p>
<p><span class="Italics">Rare</span> – adverse reactions occurring in fewer than 1/1000 patients (&lt;0.1% of patients).</p>
<table width="80%">
<col align="left" span="1" valign="top" width="15%">
<col align="left" span="1" valign="top" width="85%">
<tbody class="Headless">
<tr class="First"><td align="left"><span class="Bold">Body as a Whole</span></td></tr>
<tr>
<td align="left"><span class="Italics">Frequent  </span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, accidental <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>, <span class="product-label-link" type="condition" conceptid="4090433" conceptname="Flank pain">flank pain</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="435134" conceptname="Motor vehicle accident">motor vehicle accident</span><br><br>
</td>
</tr>
<tr><td align="left"><span class="Bold">Cardiovascular System</span></td></tr>
<tr>
<td align="left"><span class="Italics">Frequent</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Infrequent</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Rare</span></td>
<td align="left">first degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, <span class="product-label-link" type="condition" conceptid="313791" conceptname="Bundle branch block">bundle branch block</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolus</span>, <span class="product-label-link" type="condition" conceptid="314658" conceptname="Cardiomegaly">cardiomegaly</span>, <span class="product-label-link" type="condition" conceptid="443454" conceptname="Cerebral infarction">cerebral infarct</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span><br><br>
</td>
</tr>
<tr><td align="left"><span class="Bold">Digestive System</span></td></tr>
<tr>
<td align="left"><span class="Italics">Frequent</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Infrequent</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4217627" conceptname="Edema of the tongue">tongue edema</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Rare</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">gum hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4258683" conceptname="Fecal impaction">fecal impaction</span>, <span class="product-label-link" type="condition" conceptid="4171925" conceptname="Gamma-glutamyl transferase raised">gamma glutamyl transpeptidase increased</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="4167091" conceptname="Leukoplakia">leukoplakia</span> of mouth, <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">fatty liver</span> deposit, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span><br><br>
</td>
</tr>
<tr><td align="left"><span class="Bold">Endocrine</span></td></tr>
<tr>
<td align="left"><span class="Italics">Rare</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span><br><br>
</td>
</tr>
<tr><td align="left"><span class="Bold">Hemic and Lymphatic System</span></td></tr>
<tr>
<td align="left"><span class="Italics">Infrequent</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Rare</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4195171" conceptname="Normocytic hypochromic anemia">hypochromic anemia</span>, <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">lymphocytosis</span>, <span class="product-label-link" type="condition" conceptid="434910" conceptname="Monocytosis">monocytosis</span>, <span class="product-label-link" type="condition" conceptid="314617" conceptname="Basophilia">basophilia</span>, <span class="product-label-link" type="condition" conceptid="435839" conceptname="Lymphedema">lymphedema</span>, <span class="product-label-link" type="condition" conceptid="435790" conceptname="Secondary polycythemia">polycythemia</span>, <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocythemia</span><br><br>
</td>
</tr>
<tr><td align="left"><span class="Bold">Metabolic and Nutritional Disorders</span></td></tr>
<tr>
<td align="left"><span class="Italics">Infrequent</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, transaminase increased, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, creatine phosphokinase increased, alkaline phosphatase increased, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesteremia</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, lactic dehydrogenase increased, <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Rare</span></td>
<td align="left">BUN increased, creatinine increased, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipemia</span>, <span class="product-label-link" type="condition" conceptid="4266240" conceptname="Hypocholesterolemia">hypocholesteremia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">hypochloremia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span>, glucose tolerance decreased, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="4253927" conceptname="Hyperchloremia">hyperchloremia</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, hypoglycemicreaction, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, <span class="product-label-link" type="condition" conceptid="4101761" conceptname="Ketosis">ketosis</span>, <span class="product-label-link" type="condition" conceptid="4006309" conceptname="Respiratory alkalosis">respiratory alkalosis</span><br><br>
</td>
</tr>
<tr><td align="left"><span class="Bold">Musculoskeletal System</span></td></tr>
<tr>
<td align="left"><span class="Italics">Frequent</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Infrequent</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">tenosynovitis</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Rare</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span><br><br>
</td>
</tr>
<tr><td align="left"><span class="Bold">Nervous System</span></td></tr>
<tr>
<td align="left"><span class="Italics">Frequent</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal syndrome</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>, <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyric crisis</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4208094" conceptname="Cogwheel muscle rigidity">cogwheel rigidity</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="4143471" conceptname="Akinesia">akinesia</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, withdrawal syndrome, buccoglossal syndrome, <span class="product-label-link" type="condition" conceptid="4181630" conceptname="Choreoathetosis">choreoathetosis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Infrequent</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Rare</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">torticollis</span>, <span class="product-label-link" type="condition" conceptid="4015676" conceptname="Circumoral paresthesia">circumoral paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4313849" conceptname="Opisthotonus">opisthotonos</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">reflexes increased</span>, <span class="product-label-link" type="condition" conceptid="4339090" conceptname="Trismus">trismus</span><br><br>
</td>
</tr>
<tr><td align="left"><span class="Bold">Respiratory System</span></td></tr>
<tr>
<td align="left"><span class="Italics">Frequent</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Infrequent</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Rare</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngismus</span><br><br>
</td>
</tr>
<tr><td align="left"><span class="Bold">Skin and Appendages</span></td></tr>
<tr>
<td align="left"><span class="Italics">Infrequent</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">vesiculobullous rash</span><br><br>
</td>
</tr>
<tr><td align="left"><span class="Bold">Special Senses</span></td></tr>
<tr>
<td align="left"><span class="Italics">Frequent</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="137213" conceptname="Dermal mycosis">fungal dermatitis</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Infrequent</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Rare</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">eye hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defect</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratoconjunctivitis</span><br><br>
</td>
</tr>
<tr><td align="left"><span class="Bold">Urogenital System</span></td></tr>
<tr>
<td align="left"><span class="Italics">Infrequent</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">abnormal ejaculation</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span>, female lactation, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span>, male <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span>, <span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">anorgasmia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span></td>
</tr>
<tr class="Last">
<td align="left"><span class="Italics">Rare</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, female <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span>, <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine hemorrhage</span></td>
</tr>
</tbody>
</table>
<p>
 
</p>
<p></p>
<p><span class="Bold">BIPOLAR DISORDER</span></p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Acute Treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> or Mixed Episodes</span></p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Adverse Reactions Associated with Discontinuation of Treatment in Short Term, Placebo-Controlled Trials </span></p>
<p>Approximately 6.5% (18/279) of ziprasidone-treated patients in short-term, placebo-controlled studies discontinued treatment due to an adverse reaction, compared with about 3.7% (5/136) on placebo. The most common reactions associated with dropout in the ziprasidone-treated patients were <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, with 2 dropouts for each of these reactions among ziprasidone patients (1%) compared to one placebo patient each for <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (1%) and no placebo patients for the remaining adverse reactions.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Adverse Reactions Occurring at an Incidence of 2% or More Among Ziprasidone-Treated Patients in Short-Term, Oral, Placebo-Controlled Trials</span></p>
<p>Table 12 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred during acute therapy (up to 3 weeks) in patients with bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, including only those reactions that occurred in 2% or more of patients treated with ziprasidone and for which the incidence in patients treated with ziprasidone was greater than the incidence in placebo-treated patients.</p>
<a name="table12"></a><table width="80%">
<caption><span>Table 12: Treatment-Emergent Adverse Reactions Incidence In Short-Term Oral Placebo-Controlled Trials – <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> and Mixed Episodes Associated with Bipolar Disorder</span></caption>
<col align="left" span="1" valign="top" width="40%">
<col align="center" span="1" valign="top" width="30%">
<col align="center" span="1" valign="top" width="30%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1"></th>
<th align="center" colspan="2">Percentage of Patients<br> Reporting Reaction</th>
</tr>
<tr>
<th align="left" colspan="1">Body System/Adverse Reaction</th>
<th align="center" colspan="1">Ziprasidone<br> (N=279)</th>
<th align="center" colspan="1">Placebo<br> (N=136)</th>
</tr>
<tr>
<td align="left"><span class="Bold">Body as a Whole</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">18</td>
<td align="center">17</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center">6</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental Injury</span></td>
<td align="center">4</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="Bold">Cardiovascular</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td align="center">3</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left"><span class="Bold">Digestive</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">10</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">5</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></td>
<td align="center">5</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center">5</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Increased Salivation</span></td>
<td align="center">4</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4217627" conceptname="Edema of the tongue">Tongue Edema</span></td>
<td align="center">3</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left"><span class="Bold">Musculoskeletal</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left"><span class="Bold">Nervous</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center">31</td>
<td align="center">12</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span><a href="#footnote-1">*</a>
</td>
<td align="center">31</td>
<td align="center">12</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span><a href="#footnote-2">†</a>
</td>
<td align="center">16</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> </td>
<td align="center">10</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td align="center">5</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypesthesia</span></td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  Speech Disorder</td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left"><span class="Bold">Respiratory</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td align="center">3</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="Bold">Skin and Appendages</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="137213" conceptname="Dermal mycosis">Fungal Dermatitis</span></td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="Bold">Special Senses</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td align="left">  <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal Vision</span></td>
<td align="center">6</td>
<td align="center">3</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-12" href="#footnote-12" class="Sup">12</a></p>
<p><a name="footnote-reference-13" href="#footnote-13" class="Sup">13</a></p>
<p>Explorations for interactions on the basis of gender did not reveal any clinically meaningful differences in the adverse reaction occurrence on the basis of this demographic factor. </p>
<p>
 
</p>
<p></p>
<p><span class="Bold">INTRAMUSCULAR ZIPRASIDONE</span></p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Adverse Reactions Occurring at an Incidence of 1% or More Among Ziprasidone-Treated Patients in Short-Term Trials of Intramuscular Ziprasidone</span></p>
<p>Table 13 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred during acute therapy with intramuscular ziprasidone in 1% or more of patients.</p>
<p>In these studies, the most commonly observed adverse reactions associated with the use of intramuscular ziprasidone (incidence of 5% or greater) and observed at a rate on intramuscular ziprasidone (in the higher dose groups) at least twice that of the lowest intramuscular ziprasidone group were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (13%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (12%), and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (20%).</p>
<a name="table13"></a><table width="80%">
<caption><span>Table 13: Treatment-Emergent Adverse Reaction Incidence In Short-Term Fixed-Dose Intramuscular Trials</span></caption>
<col align="left" span="1" valign="top" width="40%">
<col align="center" span="1" valign="top" width="20%">
<col align="center" span="1" valign="top" width="20%">
<col align="center" span="1" valign="top" width="20%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1"></th>
<th align="center" colspan="3">Percentage of Patients Reporting Reaction</th>
</tr>
<tr>
<th align="left" colspan="1">Body System/Adverse Reaction</th>
<th align="center" colspan="1">Ziprasidone 2 mg (N=92)</th>
<th align="center" colspan="1">Ziprasidone 10 mg (N=63)</th>
<th align="center" colspan="1">Ziprasidone 20 mg (N=41)</th>
</tr>
<tr>
<td align="left"><span class="Bold">Body as a Whole</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">3</td>
<td align="center">13</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">Injection Site Pain</span></td>
<td align="center">9</td>
<td align="center">8</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center">2</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu Syndrome</span></td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left"><span class="Bold">Cardiovascular</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Postural Hypotension</span></td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td align="center">2</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  Vasodilation</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left"><span class="Bold">Digestive</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">4</td>
<td align="center">8</td>
<td align="center">12</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">Rectal Hemorrhage</span></td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">3</td>
<td align="center">3</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center">0</td>
<td align="center">3</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4122115" conceptname="Tooth disorder">Tooth Disorder</span></td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left"><span class="Bold">Nervous</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">3</td>
<td align="center">3</td>
<td align="center">10</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td align="center">2</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center">3</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center">8</td>
<td align="center">8</td>
<td align="center">20</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span></td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span></td>
<td align="center">2</td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Syndrome</span></td>
<td align="center">2</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">Hypertonia</span></td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4208094" conceptname="Cogwheel muscle rigidity">Cogwheel Rigidity</span></td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">Personality Disorder</span></td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  Speech Disorder</td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left"><span class="Bold">Respiratory</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left"><span class="Bold">Skin and Appendages</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">Furunculosis</span></td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left"><span class="Bold">Urogenital</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Dysmenorrhea</span></td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr class="Last">
<td align="left">  <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span></td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
</tbody>
</table>
<p>
 
</p>
<p></p>
<p>The following adverse reactions have been identified during post approval use of GEODON. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>Adverse reaction reports not listed above that have been received since market introduction include rare occurrences of the following : <span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> (in the presence of multiple confounding factors), <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>; <span class="Italics">Digestive System Disorders: </span><span class="product-label-link" type="condition" conceptid="4222234" conceptname="Tongue swelling">Swollen Tongue</span>; <span class="Italics">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">Galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>; <span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="374923" conceptname="Bell's palsy">Facial Droop</span>, <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span>, <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> (alone or in combination with serotonergic medicinal products), <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>; <span class="Italics">Psychiatric Disorders:</span> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>; <span class="Italics">Skin and subcutaneous Tissue Disorders:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span> (such as <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, orofacial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS); <span class="Italics">Urogenital System Disorders: </span><span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">Enuresis</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>; <span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p>
 
</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">10</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span> includes the following adverse reaction terms: <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal syndrome</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> and <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>. None of these adverse reactions occurred individually at an incidence greater than 5% in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trials.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">11</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> includes the adverse reaction terms <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">12</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span> includes the following adverse reaction terms: <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal syndrome</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> and <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>. None of these adverse reactions occurred individually at an incidence greater than 10% in bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials.</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">13</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> includes the adverse reaction terms <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>DRUG INTERACTIONS</h1>
<p class="First"></p>
<p>Drug-drug interactions can be pharmacodynamic (combined pharmacologic effects) or pharmacokinetic (alteration of plasma levels). The risks of using ziprasidone in combination with other drugs have been evaluated as described below. All interactions studies have been conducted with oral ziprasidone. Based upon the pharmacodynamic and pharmacokinetic profile of ziprasidone, possible interactions could be anticipated:</p>
<p>
 
</p>
<p></p>
<p>Approximately two-thirds of ziprasidone is metabolized via a combination of chemical reduction by glutathione and enzymatic reduction by aldehyde oxidase. There are no known clinically relevant inhibitors or inducers of aldehyde oxidase. Less than one-third of ziprasidone metabolic clearance is mediated by cytochrome P450 catalyzed oxidation.</p>
<p>
 
</p>
<p></p>
<p>An <span class="Italics">in vitro</span> enzyme inhibition study utilizing human liver microsomes showed that ziprasidone had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and thus would not likely interfere with the metabolism of drugs primarily metabolized by these enzymes. There is little potential for drug interactions with ziprasidone due to displacement <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p>   Ziprasidone should not be used with any drug that prolongs the QT interval <span class="Italics">[see <a href="#S4.1">Contraindications (4.1)</a>]</span>.</p>
<p>Given the primary CNS effects of ziprasidone, caution should be used when it is taken in combination with other centrally acting drugs.</p>
<p>Because of its potential for inducing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, ziprasidone may enhance the effects of certain antihypertensive agents.</p>
<p>Ziprasidone may antagonize the effects of levodopa and dopamine agonists.</p>
<p>
 
</p>
<p></p>
<ul><li><span class="Underline">Carbamazepine</span></li></ul>
<p>Carbamazepine is an inducer of CYP3A4; administration of 200 mg twice daily for 21 days resulted in a decrease of approximately 35% in the AUC of ziprasidone. This effect may be greater when higher doses of carbamazepine are administered. </p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Ketoconazole</span></p>
<p>Ketoconazole, a potent inhibitor of CYP3A4, at a dose of 400 mg QD for 5 days, increased the AUC and Cmax of ziprasidone by about 35–40%. Other inhibitors of CYP3A4 would be expected to have similar effects.</p>
<p>
 
</p>
<p></p>
<ul><li><span class="Underline">Cimetidine </span></li></ul>
<p>Cimetidine at a dose of 800 mg QD for 2 days did not affect ziprasidone pharmacokinetics.</p>
<p>
 
</p>
<p></p>
<ul><li><span class="Underline">Antacid</span></li></ul>
<p>The co-administration of 30 mL of Maalox® with ziprasidone did not affect the pharmacokinetics of ziprasidone.</p>
<p>
 
</p>
<p></p>
<p>Ziprasidone at a dose of 40 mg twice daily administered concomitantly with lithium at a dose of 450 mg twice daily for 7 days did not affect the steady-state level or renal clearance of lithium. Ziprasidone dosed adjunctively to lithium in a maintenance trial of bipolar patients did not affect mean therapeutic lithium levels.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">In vivo</span> studies have revealed no effect of ziprasidone on the pharmacokinetics of estrogen or progesterone components. Ziprasidone at a dose of 20 mg twice daily did not affect the pharmacokinetics of concomitantly administered oral contraceptives, ethinyl estradiol (0.03 mg) and levonorgestrel (0.15 mg).</p>
<p>
 
</p>
<p></p>
<p>Consistent with <span class="Italics">in vitro</span> results, a study in normal healthy volunteers showed that ziprasidone did not alter the metabolism of dextromethorphan, a CYP2D6 model substrate, to its major metabolite, dextrorphan. There was no statistically significant change in the urinary dextromethorphan/dextrorphan ratio.</p>
<p>
 
</p>
<p></p>
<p>A <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> of ziprasidone with valproate is unlikely due to the lack of common metabolic pathways for the two drugs. Ziprasidone dosed adjunctively to valproate in a maintenance trial of bipolar patients did not affect mean therapeutic valproate levels.</p>
<p>
 
</p>
<p></p>
<p>Population pharmacokinetic analysis of schizophrenic patients enrolled in controlled clinical trials has not revealed evidence of any clinically significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> with benztropine, propranolol, or lorazepam.</p>
<p>
 
</p>
<p></p>
<p>The absolute bioavailability of a 20 mg dose under fed conditions is approximately 60%. The absorption of ziprasidone is increased up to two-fold in the presence of food <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>USE IN SPECIFIC POPULATIONS</h1>
<p class="First"></p>
<ul>
<li>
<span class="Italics">Pregnancy</span>: Ziprasidone should be used during pregnancy only if the potential benefit justifies the potential risk. (<a href="#S8.1">8.1</a>)</li>
<li>
<span class="Italics">Nursing Mothers</span>: Breast feeding is not recommended. (<a href="#S8.3">8.3</a>)</li>
<li>
<span class="Italics">Pediatric Use</span>: Safety and effectiveness for pediatric patients has not been established. (<a href="#S8.4">8.4</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: </span>Intramuscular ziprasidone should be administered with caution to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> as the cyclodextrin excipient is cleared by renal filtration. (8.10)</li>
</ul>
<p>
 
</p>
<p></p>
<p>Pregnancy Category C</p>
<p>In animal studies ziprasidone demonstrated developmental toxicity, including possible teratogenic effects at doses similar to human therapeutic doses. When ziprasidone was administered to pregnant rabbits during the period of organogenesis, an increased incidence of fetal structural abnormalities (<span class="product-label-link" type="condition" conceptid="434462" conceptname="Ventricular septal defect">ventricular septal defects</span> and other cardiovascular malformations and kidney alterations) was observed at a dose of 30 mg/kg/day (3 times the MRHD of 200 mg/day on a mg/m<span class="Sup">2 </span>basis). There was no evidence to suggest that these developmental effects were secondary to maternal toxicity. The developmental no-effect dose was 10 mg/kg/day (equivalent to the MRHD on a mg/m<span class="Sup">2 </span>basis). In rats, embryofetal toxicity (decreased fetal weights, delayed skeletal ossification) was observed following administration of 10 to 160 mg/kg/day (0.5 to 8 times the MRHD on a mg/m<span class="Sup">2</span> basis) during organogenesis or throughout gestation, but there was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. Doses of 40 and 160 mg/kg/day (2 and 8 times the MRHD on a mg/m<span class="Sup">2</span> basis) were associated with maternal toxicity. The developmental no-effect dose was 5 mg/kg/day (0.2 times the MRHD on a mg/m<span class="Sup">2</span> basis).</p>
<p>There was an increase in the number of pups born dead and a decrease in postnatal survival through the first 4 days of lactation among the offspring of female rats treated during gestation and lactation with doses of 10 mg/kg/day (0.5 times the MRHD on a mg/m<span class="Sup">2</span> basis) or greater. Offspring <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delays</span> and neurobehavioral functional impairment were observed at doses of 5 mg/kg/day (0.2 times the MRHD on a mg/m<span class="Sup">2</span> basis) or greater. A no-effect level was not established for these effects.</p>
<p>There are no adequate and well-controlled studies in pregnant women. Ziprasidone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>
 
</p>
<p></p>
<p>Non-teratogenic Effects</p>
<p>Neonates exposed to antipsychotic drugs, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> and <span class="product-label-link" type="condition" conceptid="434750" conceptname="Feeding difficulties and mismanagement">feeding disorder</span> in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization.</p>
<p>Geodon should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>
 
</p>
<p></p>
<p>The effect of ziprasidone on labor and delivery in humans is unknown.</p>
<p>
 
</p>
<p></p>
<p>It is not known whether ziprasidone or its metabolites are excreted in human milk. It is recommended that women receiving ziprasidone should not breastfeed.</p>
<p>
 
</p>
<p></p>
<p>The safety and effectiveness of ziprasidone in pediatric patients have not been established.</p>
<p>
 
</p>
<p></p>
<p>Of the total number of subjects in clinical studies of ziprasidone, 2.4 percent were 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Nevertheless, the presence of multiple factors that might increase the pharmacodynamic response to ziprasidone, or cause poorer tolerance or orthostasis, should lead to consideration of a lower starting dose, slower titration, and careful monitoring during the initial dosing period for some elderly patients.</p>
<p>Ziprasidone intramuscular has not been systematically evaluated in elderly patients (65 years and over).</p>
<p>
 
</p>
<p></p>
<p>Because ziprasidone is highly metabolized, with less than 1% of the drug excreted unchanged, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> alone is unlikely to have a major impact on the pharmacokinetics of ziprasidone. The pharmacokinetics of ziprasidone following 8 days of 20 mg twice daily dosing were similar among subjects with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (n=27), and subjects with normal renal function, indicating that dosage adjustment based upon the degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not required. Ziprasidone is not removed by hemodialysis.</p>
<p>Intramuscular ziprasidone has not been systematically evaluated in elderly patients or in patients with hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. As the cyclodextrin excipient is cleared by renal filtration, ziprasidone intramuscular should be administered with caution to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> <span class="Italics">[see <a href="#S12">Clinical Pharmacology (12)</a>].</span></p>
<p>
 
</p>
<p></p>
<p>As ziprasidone is cleared substantially by the liver, the presence of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> would be expected to increase the AUC of ziprasidone; a multiple-dose study at 20 mg twice daily for 5 days in subjects (n=13) with clinically significant (Childs-Pugh Class A and B) cirrhosis revealed an increase in AUC <span class="Sub">0–12</span> of 13% and 34% in Childs-Pugh Class A and B, respectively, compared to a matched control group (n=14). A half-life of 7.1 hours was observed in subjects with cirrhosis compared to 4.8 hours in the control group.</p>
<p>
 
</p>
<p></p>
<p>In a multiple-dose (8 days of treatment) study involving 32 subjects, there was no difference in the pharmacokinetics of ziprasidone between men and women or between elderly (&gt;65 years) and young (18 to 45 years) subjects. Additionally, population pharmacokinetic evaluation of patients in controlled trials has revealed no evidence of clinically significant age or gender-related differences in the pharmacokinetics of ziprasidone. Dosage modifications for age or gender are, therefore, not recommended.</p>
<p>
 
</p>
<p></p>
<p>Based on <span class="Italics">in vitro</span> studies utilizing human liver enzymes, ziprasidone is not a substrate for CYP1A2; smoking should therefore not have an effect on the pharmacokinetics of ziprasidone. Consistent with these <span class="Italics">in vitro</span> results, population pharmacokinetic evaluation has not revealed any significant pharmacokinetic differences between smokers and <span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmokers</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First"></p>
<p> Ziprasidone has not been systematically studied, in animals or humans, for its potential for abuse, tolerance, or physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. While the clinical trials did not reveal any tendency for drug-seeking behavior, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which ziprasidone will be misused, diverted, and/or abused once marketed. Consequently, patients should be evaluated carefully for a history of drug abuse, and such patients should be observed closely for signs of ziprasidone misuse or abuse (e.g., development of tolerance, increases in dose, drug-seeking behavior).</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"></p>
<p>In premarketing trials involving more than 5400 patients and/or normal subjects, accidental or intentional overdosage of oral ziprasidone was documented in 10 patients. All of these patients survived without sequelae. In the patient taking the largest confirmed amount, 3,240 mg, the only symptoms reported were minimal sedation, slurring of speech, and transitory <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (200/95).</p>
<p>Adverse reactions reported with ziprasidone <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> included <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, and <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>. <span class="Italics">[see <a href="#S6.2">Adverse Reactions (6.2)</a>]</span></p>
<p>
 
</p>
<p></p>
<p> In case of acute overdosage, establish and maintain an airway and ensure adequate oxygenation and ventilation. Intravenous access should be established, and gastric lavage (after intubation, if patient is <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconscious</span>) and administration of activated charcoal together with a laxative should be considered. The possibility of <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">obtundation</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, or <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reaction</span> of the head and neck following <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may create a risk of <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> with induced <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>.</p>
<p> Cardiovascular monitoring should commence immediately and should include continuous electrocardiographic monitoring to detect possible <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>. If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of additive QT-prolonging effects that might be additive to those of ziprasidone.</p>
<p> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span> should be treated with appropriate measures such as intravenous fluids. If sympathomimetic agents are used for vascular support, epinephrine and dopamine should not be used, since beta stimulation combined with α<span class="Sub">1</span> antagonism associated with ziprasidone may worsen <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. Similarly, it is reasonable to expect that the alpha-adrenergic-blocking properties of bretylium might be additive to those of ziprasidone, resulting in problematic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p>  In cases of severe <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, anticholinergic medication should be administered. There is no specific antidote to ziprasidone, and it is not dialyzable. The possibility of multiple drug involvement should be considered. Close medical supervision and monitoring should continue until the patient recovers.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-11"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"></p>
<p>GEODON is available as capsules (ziprasidone hydrochloride) for oral administration and as an injection (ziprasidone mesylate) for intramuscular use only. Ziprasidone is a psychotropic agent that is chemically unrelated to phenothiazine or butyrophenone antipsychotic agents. It has a molecular weight of 412.94 (free base), with the following chemical name: 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2<span class="Italics">H</span>-indol-2-one. The empirical formula of C<span class="Sub">21</span>H<span class="Sub">21</span>ClN<span class="Sub">4</span>OS (free base of ziprasidone) represents the following structural formula:</p>
<p><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=036db1f2-52b3-42a0-acf9-817b7ba8c724&amp;name=MM1.jpg"></p>
<p>GEODON Capsules contain a monohydrochloride, monohydrate salt of ziprasidone. Chemically, ziprasidone hydrochloride monohydrate is 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2<span class="Italics">H</span>-indol-2-one, monohydrochloride, monohydrate. The empirical formula is C<span class="Sub">21</span>H<span class="Sub">21</span>ClN<span class="Sub">4</span>OS ∙ HCl ∙ H<span class="Sub">2</span>O and its molecular weight is 467.42. Ziprasidone hydrochloride monohydrate is a white to slightly pink powder.</p>
<p>GEODON Capsules are supplied for oral administration in 20 mg (blue/white), 40 mg (blue/blue), 60 mg (white/white), and 80 mg (blue/white) capsules. GEODON Capsules contain ziprasidone hydrochloride monohydrate, lactose, pregelatinized starch, and magnesium stearate.</p>
<p>GEODON for Injection contains a lyophilized form of ziprasidone mesylate trihydrate. Chemically, ziprasidone mesylate trihydrate is 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2<span class="Italics">H</span>-indol-2-one, methanesulfonate, trihydrate. The empirical formula is C<span class="Sub">21</span>H<span class="Sub">21</span>ClN<span class="Sub">4</span>OS ∙ CH<span class="Sub">3</span>SO<span class="Sub">3</span>H ∙ 3H<span class="Sub">2</span>O and its molecular weight is 563.09.</p>
<p>GEODON for Injection is available in a single-dose vial as ziprasidone mesylate (20 mg ziprasidone/mL when reconstituted according to label instructions) <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a>].</span> Each mL of ziprasidone mesylate for injection (when reconstituted) contains 20 mg of ziprasidone and 4.7 mg of methanesulfonic acid solubilized by 294 mg of sulfobutylether β-cyclodextrin sodium (SBECD).</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-12"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<p>The mechanism of action of ziprasidone, as with other drugs having efficacy in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, is unknown. However, it has been proposed that this drug's efficacy in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> is mediated through a combination of dopamine type 2 (D<span class="Sub">2</span>) and serotonin type 2 (5HT<span class="Sub">2</span>) antagonism. As with other drugs having efficacy in bipolar disorder, the mechanism of action of ziprasidone in bipolar disorder is unknown.</p>
<p>
 
</p>
<p></p>
<p>Ziprasidone exhibited high <span class="Italics">in vitro</span> binding affinity for the dopamine D<span class="Sub">2</span> and D<span class="Sub">3</span>, the serotonin 5HT<span class="Sub">2A</span>, 5HT<span class="Sub">2C</span>, 5HT<span class="Sub">1A</span>, 5HT<span class="Sub">1D</span>, and α<span class="Sub">1</span>-adrenergic receptors (K<span class="Sub">i </span>s of 4.8, 7.2, 0.4, 1.3, 3.4, 2, and 10 nM, respectively), and moderate affinity for the histamine H<span class="Sub">1</span> receptor (K<span class="Sub">i</span>=47 nM). Ziprasidone functioned as an antagonist at the D<span class="Sub">2,</span> 5HT<span class="Sub">2A</span>, and 5HT<span class="Sub">1D</span> receptors, and as an agonist at the 5HT<span class="Sub">1A</span> receptor. Ziprasidone inhibited synaptic reuptake of serotonin and norepinephrine. No appreciable affinity was exhibited for other receptor/binding sites tested, including the cholinergic muscarinic receptor (IC<span class="Sub">50</span> &gt;1 µM). Antagonism at receptors other than dopamine and 5HT<span class="Sub">2</span> with similar receptor affinities may explain some of the other therapeutic and side effects of ziprasidone. Ziprasidone's antagonism of histamine H<span class="Sub">1</span> receptors may explain the <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> observed with this drug. Ziprasidone's antagonism of α<span class="Sub">1</span>-adrenergic receptors may explain the <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> observed with this drug.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Oral Pharmacokinetics</span></p>
<p>Ziprasidone's activity is primarily due to the parent drug. The multiple-dose pharmacokinetics of ziprasidone are dose-proportional within the proposed clinical dose range, and ziprasidone accumulation is predictable with multiple dosing. Elimination of ziprasidone is mainly via hepatic metabolism with a mean terminal half-life of about 7 hours within the proposed clinical dose range. Steady-state concentrations are achieved within one to three days of dosing. The mean apparent systemic clearance is 7.5 mL/min/kg. Ziprasidone is unlikely to interfere with the metabolism of drugs metabolized by cytochrome P450 enzymes.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="Underline">Absorption</span>:</span> Ziprasidone is well absorbed after oral administration, reaching peak plasma concentrations in 6 to 8 hours. The absolute bioavailability of a 20 mg dose under fed conditions is approximately 60%. The absorption of ziprasidone is increased up to two-fold in the presence of food.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="Underline">Distribution</span>:</span> Ziprasidone has a mean apparent volume of distribution of 1.5 L/kg. It is greater than 99% bound to plasma proteins, binding primarily to albumin and α<span class="Sub">1</span>-acid glycoprotein. The <span class="Italics">in vitro</span> plasma protein binding of ziprasidone was not altered by warfarin or propranolol, two highly protein-bound drugs, nor did ziprasidone alter the binding of these drugs in human plasma. Thus, the potential for drug interactions with ziprasidone due to displacement is minimal.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="Underline">Metabolism and Elimination</span>:</span> Ziprasidone is extensively metabolized after oral administration with only a small amount excreted in the urine (&lt;1%) or feces (&lt;4%) as unchanged drug. Ziprasidone is primarily cleared via three metabolic routes to yield four major circulating metabolites, benzisothiazole (BITP) sulphoxide, BITP-sulphone, ziprasidone sulphoxide, and S-methyldihydroziprasidone. Approximately 20% of the dose is excreted in the urine, with approximately 66% being eliminated in the feces. Unchanged ziprasidone represents about 44% of total drug-related material in serum. <span class="Italics">In vitro</span> studies using human liver subcellular fractions indicate that S-methyldihydroziprasidone is generated in two steps. These studies indicate that the reduction reaction is mediated primarily by chemical reduction by glutathione as well as by enzymatic reduction by aldehyde oxidase and the subsequent methylation is mediated by thiol methyltransferase. <span class="Italics">In vitro</span> studies using human liver microsomes and recombinant enzymes indicate that CYP3A4 is the major CYP contributing to the oxidative metabolism of ziprasidone. CYP1A2 may contribute to a much lesser extent. Based on <span class="Italics">in vivo</span> abundance of excretory metabolites, less than one-third of ziprasidone metabolic clearance is mediated by cytochrome P450 catalyzed oxidation and approximately two-thirds via reduction. There are no known clinically relevant inhibitors or inducers of aldehyde oxidase.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Intramuscular Pharmacokinetics</span></p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="Underline">Systemic Bioavailability</span>:</span> The bioavailability of ziprasidone administered intramuscularly is 100%. After intramuscular administration of single doses, peak serum concentrations typically occur at approximately 60 minutes post-dose or earlier and the mean half-life (T<span class="Sub">½</span>) ranges from two to five hours. Exposure increases in a dose-related manner and following three days of intramuscular dosing, little accumulation is observed.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="Underline">Metabolism and Elimination</span>:</span> Although the metabolism and elimination of IM ziprasidone have not been systematically evaluated, the intramuscular route of administration would not be expected to alter the metabolic pathways.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-13"></a><p></p>
<h1>NONCLINICAL TOXICOLOGY</h1>
<p class="First"></p>
<p><span class="Bold">Carcinogenesis</span></p>
<p>Lifetime carcinogenicity studies were conducted with ziprasidone in Long Evans rats and CD-1 mice. Ziprasidone was administered for 24 months in the diet at doses of 2, 6, or 12 mg/kg/day to rats, and 50, 100, or 200 mg/kg/day to mice (0.1 to 0.6 and 1 to 5 times the maximum recommended human dose [MRHD] of 200 mg/day on a mg/m<span class="Sup">2</span> basis, respectively). In the rat study, there was no evidence of an increased incidence of tumors compared to controls. In male mice, there was no increase in incidence of tumors relative to controls. In female mice, there were dose-related increases in the incidences of pituitary gland <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenoma</span> and carcinoma, and mammary gland adenocarcinoma at all doses tested (50 to 200 mg/kg/day or 1 to 5 times the MRHD on a mg/m<span class="Sup">2</span> basis). Proliferative changes in the pituitary and mammary glands of rodents have been observed following chronic administration of other antipsychotic agents and are considered to be prolactin-mediated. Increases in serum prolactin were observed in a 1-month dietary study in female, but not male, mice at 100 and 200 mg/kg/day (or 2.5 and 5 times the MRHD on a mg/m<span class="Sup">2</span> basis). Ziprasidone had no effect on serum prolactin in rats in a 5-week dietary study at the doses that were used in the carcinogenicity study. The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents is unknown <span class="Italics">[see <a href="#S5.12">Warnings and Precautions (5.12)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Mutagenesis</span></p>
<p>Ziprasidone was tested in the Ames bacterial mutation assay, the <span class="Italics">in vitro </span>mammalian cell gene mutation mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, the <span class="Italics">in vitro</span> chromosomal aberration assay in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and the <span class="Italics">in vivo </span>chromosomal aberration assay in mouse bone marrow. There was a reproducible mutagenic response in the Ames assay in one <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">S. typhimurium</span> in the absence of metabolic activation. Positive results were obtained in both the <span class="Italics">in vitro</span> mammalian cell gene mutation assay and the <span class="Italics">in vitro</span> chromosomal aberration assay in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Impairment of Fertility </span></p>
<p>Ziprasidone was shown to increase time to copulation in Sprague-Dawley rats in two fertility and early embryonic development studies at doses of 10 to 160 mg/kg/day (0.5 to 8 times the MRHD of 200 mg/day on a mg/m<span class="Sup">2</span> basis). Fertility rate was reduced at 160 mg/kg/day (8 times the MRHD on a mg/m<span class="Sup">2</span> basis). There was no effect on fertility at 40 mg/kg/day (2 times the MRHD on a mg/m<span class="Sup">2</span> basis). The effect on fertility appeared to be in the female since fertility was not impaired when males given 160 mg/kg/day (8 times the MRHD on a mg/m<span class="Sup">2</span> basis) were mated with untreated females. In a 6-month study in male rats given 200 mg/kg/day (10 times the MRHD on a mg/m<span class="Sup">2</span> basis) there were no treatment-related findings observed in the testes.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-14"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First"></p>
<p>The efficacy of oral ziprasidone in the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> was evaluated in 5 placebo-controlled studies, 4 short-term (4- and 6-week) trials and one maintenance trial. All trials were in adult inpatients, most of whom met DSM III-R criteria for <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. Each study included 2 to 3 fixed doses of ziprasidone as well as placebo. Four of the 5 trials were able to distinguish ziprasidone from placebo; one short-term study did not. Although a single fixed-dose haloperidol arm was included as a comparative treatment in one of the three short-term trials, this single study was inadequate to provide a reliable and valid comparison of ziprasidone and haloperidol.</p>
<p>Several instruments were used for assessing psychiatric signs and symptoms in these studies. The Brief Psychiatric Rating Scale (BPRS) and the Positive and Negative Syndrome Scale (PANSS) are both multi-item inventories of general psychopathology usually used to evaluate the effects of drug treatment in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. The BPRS <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> cluster (conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) is considered a particularly useful subset for assessing actively <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> schizophrenic patients. A second widely used assessment, the Clinical Global Impression (CGI), reflects the impression of a skilled observer, fully familiar with the manifestations of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, about the overall clinical state of the patient. In addition, the Scale for Assessing Negative Symptoms (SANS) was employed for assessing negative symptoms in one trial.</p>
<p><span class="Bold">The results of the oral ziprasidone trials in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> follow:</span></p>
<ul>
<li>In a 4-week, placebo-controlled trial (n=139) comparing 2 fixed doses of ziprasidone (20 and 60 mg twice daily) with placebo, only the 60 mg dose was superior to placebo on the BPRS total score and the CGI severity score. This higher dose group was not superior to placebo on the BPRS <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> cluster or on the SANS.</li>
<li>In a 6-week, placebo-controlled trial (n=302) comparing 2 fixed doses of ziprasidone (40 and 80 mg twice daily) with placebo, both dose groups were superior to placebo on the BPRS total score, the BPRS <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> cluster, the CGI severity score and the PANSS total and negative subscale scores. Although 80 mg twice daily had a numerically greater effect than 40 mg twice daily, the difference was not statistically significant.</li>
<li>In a 6-week, placebo-controlled trial (n=419) comparing 3 fixed doses of ziprasidone (20, 60, and 100 mg twice daily) with placebo, all three dose groups were superior to placebo on the PANSS total score, the BPRS total score, the BPRS <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> cluster, and the CGI severity score. Only the 100 mg twice daily dose group was superior to placebo on the PANSS negative subscale score. There was no clear evidence for a dose-response relationship within the 20 mg twice daily to 100 mg twice daily dose range.</li>
<li>In a 4-week, placebo-controlled trial (n=200) comparing 3 fixed doses of ziprasidone (5, 20, and 40 mg twice daily), none of the dose groups was statistically superior to placebo on any outcome of interest.</li>
<li>A study was conducted in stable chronic or subchronic (CGI-S ≤5 at baseline) schizophrenic inpatients (n=294) who had been hospitalized for not less than two months. After a 3-day single-blind placebo run-in, subjects were randomized to one of 3 fixed doses of ziprasidone (20 mg, 40 mg, or 80 mg twice daily) or placebo and observed for relapse. Patients were observed for "impending <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> relapse," defined as CGI-improvement score of ≥6 (much worse or very much worse) and/or scores ≥6 (moderately severe) on the <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span> or uncooperativeness items of the PANSS on two consecutive days. Ziprasidone was significantly superior to placebo in time to relapse, with no significant difference between the different dose groups. There were insufficient data to examine population subsets based on age and race. Examination of population subsets based on gender did not reveal any differential responsiveness.</li>
</ul>
<p>
 
</p>
<p></p>
<p><span class="Bold">Acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> and Mixed Episodes Associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> </span></p>
<p>The efficacy of ziprasidone was established in 2 placebo-controlled, double-blind, 3-week monotherapy studies in patients meeting DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episode with or without <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> features. Primary rating instruments used for assessing <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> symptoms in these trials were: (1) the <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> Rating Scale (MRS), which is derived from the Schedule for <span class="product-label-link" type="condition" conceptid="444100" conceptname="Mood disorder">Affective Disorders</span> and <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span>-Change Version (SADS-CB) with items grouped as the <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> Syndrome subscale (<span class="product-label-link" type="condition" conceptid="4304866" conceptname="Elevated mood">elevated mood</span>, less need for sleep, excessive energy, excessive activity, grandiosity), the Behavior and Ideation subscale (<span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, motor <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, accelerated speech, <span class="product-label-link" type="condition" conceptid="4115026" conceptname="Racing thoughts">racing thoughts</span>, poor judgment) and impaired insight; and (2) the Clinical Global Impression-Severity of Illness Scale (CGI-S), which was used to assess the clinical significance of treatment response.</p>
<p>The results of the oral ziprasidone trials in adult <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>/mixed episode follow<span class="Bold">:</span> in a 3-week placebo-controlled trial (n=210), the dose of ziprasidone was 40 mg twice daily on Day 1 and 80 mg twice daily on Day 2. Titration within the range of 40–80 mg twice daily (in 20 mg twice daily increments) was permitted for the duration of the study. Ziprasidone was significantly more effective than placebo in reduction of the MRS total score and the CGI-S score. The mean daily dose of ziprasidone in this study was 132 mg. In a second 3-week placebo-controlled trial (n=205), the dose of ziprasidone was 40 mg twice daily on Day 1. Titration within the range of 40–80 mg twice daily (in 20 mg twice daily increments) was permitted for the duration of study (beginning on Day 2). Ziprasidone was significantly more effective than placebo in reduction of the MRS total score and the CGI-S score. The mean daily dose of ziprasidone in this study was 112 mg.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Maintenance Therapy </span></p>
<p>The efficacy of ziprasidone as adjunctive therapy to lithium or valproate in the maintenance treatment of <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> was established in a placebo-controlled trial in patients who met DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span>. The trial included patients whose most recent episode was <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed, with or without <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> features. In the open-label phase, patients were required to be stabilized on ziprasidone plus lithium or valproic acid for at least 8 weeks in order to be randomized. In the double-blind randomized phase, patients continued treatment with lithium or valproic acid and were randomized to receive either ziprasidone (administered twice daily totaling 80 mg to 160 mg per day) or placebo. Generally, in the maintenance phase, patients continued on the same dose on which they were stabilized during the stabilization phase. The primary endpoint in this study was time to recurrence of a mood episode (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>, mixed or depressed episode) requiring intervention, which was defined as any of the following: discontinuation due to a mood episode, clinical intervention for a mood episode (e.g., initiation of medication or hospitalization), or <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> Rating Scale score ≥ 18 or a MADRS score ≥18 (on 2 consecutive assessments no more than 10 days apart). A total of 584 subjects were treated in the open-label stabilization period. In the double-blind randomization period, 127 subjects were treated with ziprasidone, and 112 subjects were treated with placebo. Ziprasidone was superior to placebo in increasing the time to recurrence of a mood episode. The types of relapse events observed included depressive, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>, and mixed episodes. Depressive, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>, and mixed episodes accounted for 53%, 34%, and 13%, respectively, of the total number of relapse events in the study.</p>
<p>
 
</p>
<p></p>
<p>The efficacy of intramuscular ziprasidone in the management of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> schizophrenic patients was established in two short-term, double-blind trials of schizophrenic subjects who were considered by the investigators to be "acutely <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span>" and in need of IM antipsychotic medication. In addition, patients were required to have a score of 3 or more on at least 3 of the following items of the PANSS: <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span> and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span>. Efficacy was evaluated by analysis of the area under the curve (AUC) of the Behavioural Activity Rating Scale (BARS) and Clinical Global Impression (CGI) severity rating. The BARS is a seven point scale with scores ranging from 1 (difficult or unable to rouse) to 7 (violent, requires restraint). Patients' scores on the BARS at baseline were mostly 5 (signs of overt activity [physical or verbal], calms down with instructions) and as determined by investigators, exhibited a degree of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> that warranted intramuscular therapy. There were few patients with a rating higher than 5 on the BARS, as the most severely <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> patients were generally unable to provide informed consent for participation in premarketing clinical trials.</p>
<p>Both studies compared higher doses of ziprasidone intramuscular with a 2 mg control dose. In one study, the higher dose was 20 mg, which could be given up to 4 times in the 24 hours of the study, at interdose intervals of no less than 4 hours. In the other study, the higher dose was 10 mg, which could be given up to 4 times in the 24 hours of the study, at interdose intervals of no less than 2 hours.</p>
<p><span class="Bold">The results of the intramuscular ziprasidone trials follow:</span></p>
<p>(1)In a one-day, double-blind, randomized trial (n=79) involving doses of ziprasidone intramuscular of 20 mg or 2 mg, up to QID, ziprasidone intramuscular 20 mg was statistically superior to ziprasidone intramuscular 2 mg, as assessed by AUC of the BARS at 0 to 4 hours, and by CGI severity at 4 hours and study endpoint.(2)In another one-day, double-blind, randomized trial (n=117) involving doses of ziprasidone intramuscular of 10 mg or 2 mg, up to QID, ziprasidone intramuscular 10 mg was statistically superior to ziprasidone intramuscular 2 mg, as assessed by AUC of the BARS at 0 to 2 hours, but not by CGI severity.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<p>GEODON Capsules are differentiated by capsule color/size and are imprinted in black ink with "Pfizer and ZDX [dosage strength]" or with "Pfizer" and a unique number. GEODON Capsules are supplied for oral administration in 20 mg (blue/white), 40 mg (blue/blue), 60 mg (white/white), and 80 mg (blue/white) capsules. They are supplied in the following strengths and package configurations:</p>
<table width="80%">
<caption><span>GEODON Capsules</span></caption>
<col align="left" span="1" valign="top" width="25%">
<col align="center" span="1" valign="top" width="20%">
<col align="center" span="1" valign="top" width="35%">
<col align="center" span="1" valign="top" width="20%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Package Configuration</th>
<th align="center" colspan="1">Capsule Strength (mg)</th>
<th align="center" colspan="1">NDC Code</th>
<th align="center" colspan="1">Imprint</th>
</tr>
<tr>
<td align="left">Bottles of 60</td>
<td align="center">20</td>
<td align="center">0049-0052-60</td>
<td align="center">ZDX 20</td>
</tr>
<tr>
<td align="left">Bottles of 60</td>
<td align="center">40</td>
<td align="center">0049-0054-60</td>
<td align="center">ZDX 40</td>
</tr>
<tr>
<td align="left">Bottles of 60</td>
<td align="center">60</td>
<td align="center">0049-0056-60</td>
<td align="center">ZDX 60</td>
</tr>
<tr>
<td align="left">Bottles of 60</td>
<td align="center">80</td>
<td align="center">0049-0058-60</td>
<td align="center">ZDX 80</td>
</tr>
<tr>
<td align="left">Unit dose/80</td>
<td align="center">20</td>
<td align="center">0049-0052-80</td>
<td align="center">ZDX 20</td>
</tr>
<tr>
<td align="left">Unit dose/80</td>
<td align="center">40</td>
<td align="center">0049-0054-80</td>
<td align="center">ZDX 40</td>
</tr>
<tr>
<td align="left">Unit dose/80</td>
<td align="center">60</td>
<td align="center">0049-0056-80</td>
<td align="center">ZDX 60</td>
</tr>
<tr class="Last">
<td align="left">Unit dose/80</td>
<td align="center">80</td>
<td align="center">0049-0058-80</td>
<td align="center">ZDX 80</td>
</tr>
</tbody>
</table>
<p>or</p>
<table width="80%">
<caption><span>GEODON Capsules</span></caption>
<col align="left" span="1" valign="top" width="25%">
<col align="center" span="1" valign="top" width="20%">
<col align="center" span="1" valign="top" width="35%">
<col align="center" span="1" valign="top" width="20%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Package Configuration</th>
<th align="center" colspan="1">Capsule Strength (mg)</th>
<th align="center" colspan="1">NDC Code</th>
<th align="center" colspan="1">Imprint</th>
</tr>
<tr>
<td align="left">Bottles of 60</td>
<td align="center">20</td>
<td align="center">NDC-0049-3960-60</td>
<td align="center">396</td>
</tr>
<tr>
<td align="left">Bottles of 60</td>
<td align="center">40</td>
<td align="center">NDC-0049-3970-60</td>
<td align="center">397</td>
</tr>
<tr>
<td align="left">Bottles of 60</td>
<td align="center">60</td>
<td align="center">NDC-0049-3980-60</td>
<td align="center">398</td>
</tr>
<tr>
<td align="left">Bottles of 60</td>
<td align="center">80</td>
<td align="center">NDC-0049-3990-60</td>
<td align="center">399</td>
</tr>
<tr>
<td align="left">Unit dose/80</td>
<td align="center">20</td>
<td align="center">NDC-0049-3960-41</td>
<td align="center">396</td>
</tr>
<tr>
<td align="left">Unit dose/80</td>
<td align="center">40</td>
<td align="center">NDC-0049-3970-41</td>
<td align="center">397</td>
</tr>
<tr>
<td align="left">Unit dose/80</td>
<td align="center">60</td>
<td align="center">NDC-0049-3980-41</td>
<td align="center">398</td>
</tr>
<tr class="Last">
<td align="left">Unit dose/80</td>
<td align="center">80</td>
<td align="center">NDC-0049-3990-41</td>
<td align="center">399</td>
</tr>
</tbody>
</table>
<p>
 
</p>
<p></p>
<p>GEODON Capsules should be stored at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].</p>
<p>
 
</p>
<p></p>
<p>GEODON for Injection is available in a single-dose vial as ziprasidone mesylate (20 mg ziprasidone/mL when reconstituted according to label instructions) <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a>]</span>. Each mL of ziprasidone mesylate for injection (when reconstituted) affords a colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> pink solution that contains 20 mg of ziprasidone and 4.7 mg of methanesulfonic acid solubilized by 294 mg of sulfobutylether β-cyclodextrin sodium (SBECD).</p>
<table width="90%">
<caption><span>GEODON for Injection</span></caption>
<col align="center" span="1" valign="middle" width="40%">
<col align="center" span="1" valign="middle" width="30%">
<col align="center" span="1" valign="middle" width="30%">
<tbody class="Headless">
<tr class="First">
<th align="center" colspan="1">Package</th>
<th align="center" colspan="1">Concentration</th>
<th align="center" colspan="1">NDC Code</th>
</tr>
<tr class="Last">
<td align="center">Single-use Vials (carton of 10 vials)</td>
<td align="center">20 mg/mL</td>
<td align="center">NDC-0049-3920-83</td>
</tr>
</tbody>
</table>
<p>
 
</p>
<p></p>
<p>GEODON for Injection should be stored at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature] in dry form. Protect from light. Following reconstitution, GEODON for Injection can be stored, when protected from light, for up to 24 hours at 15°C to 30°C (59°F to 86°F) or up to 7 days refrigerated, 2°C to 8°C (36°F to 46°F).</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-16"></a><p></p>
<h1>INFORMATION FOR PATIENTS</h1>
<p class="First"></p>
<p><span class="Italics">See <a href="#S17.4">FDA-Approved Patient Labeling (17.4)</a></span>.</p>
<p>Please refer to the patient package insert. To assure safe and effective use of GEODON, the information and instructions provided in the patient information should be discussed with patients.</p>
<p>
 
</p>
<p></p>
<p>Patients should be instructed to take GEODON Capsules with food for optimal absorption. The absorption of ziprasidone is increased up to two-fold in the presence of food <span class="Italics">[see <a href="#S7.8">Drug Interactions (7.8)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p>Patients should be advised to inform their health care providers of the following: History of QT prolongation; recent <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>; uncompensated <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>; prescription of other drugs that have demonstrated QT prolongation; risk for significant electrolyte abnormalities; and history of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span> <span class="Italics">[see <a href="#S4.1">Contraindications (4.1)</a> and <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</p>
<p>Patients should be instructed to report the onset of any conditions that put them at risk for significant <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> in particular, including but not limited to the initiation of diuretic therapy or prolonged <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. In addition, patients should be instructed to report symptoms such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> to the prescriber <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p>    Patients should be instructed to report to their health care provider at the earliest onset any signs or symptoms that may be associated with Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS) [see <a href="#S5.4">Warnings and Precautions (5.4)</a>].</p>
<p>
 
</p>
<p></p>
<p> </p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=036db1f2-52b3-42a0-acf9-817b7ba8c724&amp;name=MM2.jpg"></p>
<p>LAB-0273-24.0</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-18"></a><p></p>
<h1>SPL PATIENT PACKAGE INSERT</h1>
<p class="First"></p>
<p>PATIENT SUMMARY OF INFORMATION ABOUT<br><span class="Bold">GEODON<span class="Sup">®</span> Capsules</span><br>(ziprasidone HCl)</p>
<p><span class="Bold">Information for patients taking GEODON or their caregivers</span></p>
<p>This summary contains important information about GEODON. It is not meant to take the place of your doctor's instructions. Read this information carefully before you take GEODON. Ask your doctor or pharmacist if you do not understand any of this information or if you want to know more about GEODON.</p>
<p><span class="Bold">What Is GEODON?</span></p>
<p>GEODON is a type of prescription medicine called a psychotropic, also known as an atypical antipsychotic. GEODON can be used to treat symptoms of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes associated with bipolar disorder. GEODON can also be used as maintenance treatment of bipolar disorder when added to lithium or valproate.</p>
<p><span class="Bold">Who Should Take GEODON?</span></p>
<p>Only your doctor can know if GEODON is right for you. GEODON may be prescribed for you if you have <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or bipolar disorder.</p>
<p>Symptoms of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> may include:</p>
<ul>
<li>hearing voices, seeing things, or sensing things that are not there (<span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>)</li>
<li>beliefs that are not true (<span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusions</span>)</li>
<li>unusual suspiciousness (<span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>)</li>
<li>becoming withdrawn from family and friends</li>
</ul>
<p>Symptoms of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes of bipolar disorder may include:</p>
<ul>
<li>extremely high or <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritable</span> mood</li>
<li>increased energy, activity, and <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4115026" conceptname="Racing thoughts">racing thoughts</span> or talking very fast</li>
<li>easily distracted</li>
<li>little need for sleep</li>
</ul>
<p>If you show a response to GEODON, your symptoms may improve. If you continue to take GEODON there is less chance of your symptoms returning. Do not stop taking the capsules even when you feel better without first discussing it with your doctor.</p>
<p>It is also important to remember that GEODON capsules should be taken with food.</p>
<p><span class="Bold">What is the most important safety information I should know about GEODON?</span></p>
<p><span class="Bold">GEODON is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. Elderly patients with a diagnosis of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> related to <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> treated with antipsychotics are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> when compared to patients who are treated with placebo (a sugar pill).</span></p>
<p>GEODON is an effective drug to treat the symptoms of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and the <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes of bipolar disorder. However, one potential side effect is that it may change the way the electrical current in your heart works more than some other drugs. The change is small and it is not known whether this will be harmful, but some other drugs that cause this kind of change have in rare cases caused dangerous heart rhythm abnormalities<span class="Bold">.</span> Because of this, GEODON should be used only after your doctor has considered this risk for GEODON against the risks and benefits of other medications available for treating <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> and mixed episodes.</p>
<p><span class="Bold">Your risk of dangerous changes in heart rhythm can be increased if you are taking certain other medicines and if you already have certain abnormal heart conditions. Therefore, it is important to tell your doctor about any other medicines that you take, including non-prescription medicines, supplements, and herbal medicines. You must also tell your doctor about any heart problems you have or have had.</span></p>
<p><span class="Bold">Who should NOT take GEODON?</span></p>
<p>Elderly patients with a diagnosis of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> related to <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. GEODON is not approved for the treatment of these patients.</p>
<p>Anything that can increase the chance of a heart rhythm abnormality should be avoided. Therefore, do not take GEODON if:</p>
<ul>
<li>You have certain heart diseases, for example, <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>, a recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or certain irregularities of heart rhythm (discuss the specifics with your doctor)</li>
<li>You are currently taking medications that should not be taken in combination with ziprasidone, for example, dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol or tacrolimus.</li>
</ul>
<p><span class="Bold">What To Tell Your Doctor Before You Start GEODON</span></p>
<p>Only your doctor can decide if GEODON is right for you. Before you start GEODON, be sure to tell your doctor if you:</p>
<ul>
<li>have had any problem with the way your heart beats or any heart related illness or disease</li>
<li>any family history of heart disease, including recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></li>
<li>have had any problem with <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li>are taking or have recently taken any prescription medicines</li>
<li>are taking any over-the-counter medicines you can buy without a prescription, including natural/herbal remedies</li>
<li>have had any problems with your liver</li>
<li>are pregnant, might be pregnant, or plan to get pregnant</li>
<li>are breast feeding</li>
<li>are allergic to any medicines</li>
<li>have ever had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to ziprasidone or any of the other ingredients of GEODON capsules. Ask your doctor or pharmacist for a list of these ingredients</li>
<li>have low levels of potassium or magnesium in your blood</li>
</ul>
<p>Your doctor may want you to get additional laboratory tests to see if GEODON is an appropriate treatment for you.</p>
<p><span class="Bold">GEODON And Other Medicines</span></p>
<p>There are some medications that may be unsafe to use when taking GEODON, and there are some medicines that can affect how well GEODON works. While you are on GEODON, check with your doctor before starting any new prescription or over-the-counter medications, including natural/herbal remedies. </p>
<p><span class="Bold">How To Take GEODON</span></p>
<ul>
<li>Take GEODON only as directed by your doctor.</li>
<li>Swallow the capsules whole.</li>
<li>Take GEODON capsules with food.</li>
<li>It is best to take GEODON at the same time each day.</li>
<li>GEODON may take a few weeks to work. It is important to be patient.</li>
<li>Do not change your dose or stop taking your medicine without your doctor's approval.</li>
<li>Remember to keep taking your capsules, even when you feel better.</li>
</ul>
<p><span class="Bold">Possible Side Effects</span></p>
<p>Because these problems could mean you're having a heart rhythm abnormality, contact your doctor <span>IMMEDIATELY</span> if you:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Faint</span> or lose consciousness</li>
<li>Feel a change in the way that your heart beats (<span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>)</li>
</ul>
<p>Common side effects of GEODON include the following and should also be discussed with your doctor if they occur:</p>
<ul>
<li>Feeling unusually tired or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> or <span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span></li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span></li>
<li>Abnormal muscle movements, including <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, shuffling, and uncontrolled involuntary movements</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></li>
<li>Increased <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> / <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span></li>
</ul>
<p>If you develop any side effects that concern you, talk with your doctor. It is particularly important to tell your doctor if you have <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or another illness that can cause you to lose fluids. Your doctor may want to check your blood to make sure that you have the right amount of important salts after such illnesses. </p>
<p>For a list of all side effects that have been reported, ask your doctor or pharmacist for the GEODON Professional Package Insert.</p>
<p><span class="Bold">What To Do For An <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></span></p>
<p>In case of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, call your doctor or poison control center right away or go to the nearest emergency room.</p>
<p><span class="Bold">Other Important Safety Information</span></p>
<p>A serious condition called <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span> (NMS) can occur with all antipsychotic medications including GEODON. Signs of NMS include very high <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, rigid muscles, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, or increased heart rate and blood pressure. NMS is a rare but serious side effect that could be fatal. Therefore, tell your doctor if you experience any of these signs.</p>
<p>Delayed-onset drug reaction called drug reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and systemic symptoms (DRESS) can occur with ziprasidone. Signs of DRESS may include <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">swollen lymph nodes</span>. DRESS is sometimes fatal; therefore, tell your doctor immediately if you experience any of these signs.</p>
<p>Adverse reactions related to high blood sugar (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>), sometimes serious, have been reported in patients treated with atypical antipsychotics. There have been few reports of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> in patients treated with GEODON, and it is not known if GEODON is associated with these reactions. Patients treated with an atypical antipsychotic should be monitored for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> caused by a drop in your blood pressure may occur with GEODON, especially when you first start taking this medication or when the dose is increased. If this happens, be careful not to stand up too quickly, and talk to your doctor about the problem.</p>
<p>Before taking GEODON, tell your doctor if you are pregnant or plan on becoming pregnant. It is advised that you don't breast feed an infant if you are taking GEODON. </p>
<p>Because GEODON can cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, be careful when operating machinery or driving a motor vehicle.</p>
<p>Since medications of the same drug class as GEODON may interfere with the ability of the body to adjust to heat, it is best to avoid situations involving <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">high temperature</span> or humidity. </p>
<p>It is best to avoid consuming alcoholic beverages while taking GEODON. </p>
<p>Call your doctor <span>immediately</span> if you take more than the amount of GEODON prescribed by your doctor.</p>
<p>GEODON has not been shown to be safe or effective in the treatment of children and teenagers under the age of 18 years old.</p>
<p><span class="Bold">Keep GEODON and all medicines out of the reach of children.</span></p>
<p><span class="Bold">How To Store GEODON</span></p>
<p>Store GEODON capsules at room temperature (59°F to 86°F or 15°C to 30°C).</p>
<p><span class="Bold">For More Information About GEODON</span></p>
<p>This sheet is only a summary. GEODON is a prescription medicine and only your doctor can decide if it is right for you. If you have any questions or want more information about GEODON, talk with your doctor or pharmacist. You can also visit www.geodon.com.</p>
<p>This product's label may have been updated. For current full prescribing information, please visit www.pfizer.com</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First">
    DRUG: Geodon </p>
<p><br></p>
<p>GENERIC: ziprasidone mesylate</p>
<p><br></p>
<p>DOSAGE: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION</p>
<p><br></p>
<p>ADMINSTRATION: INTRAMUSCULAR</p>
<p><br></p>
<p>NDC: 61786-172-01</p>
<p><br></p>
<p>ACTIVE INGREDIENT(S):</p>
<ul><li>ZIPRASIDONE MESYLATE 20mg in 1mL</li></ul>
<p><br></p>
<p>INACTIVE INGREDIENT(S):</p>
<ul>
<li>METHANESULFONIC ACID</li>
<li>SULFOBUTYLETHER .BETA.-CYCLODEXTRIN</li>
</ul>
<p><br></p>
<p>PACKAGING: 1 mL in 1 VIAL, SINGLE-DOSE</p>
<p><br></p>
<p><br></p>
<p><br></p>
<p><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=036db1f2-52b3-42a0-acf9-817b7ba8c724&amp;name=MM3.jpg"></p>
<p><img alt="MM4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=036db1f2-52b3-42a0-acf9-817b7ba8c724&amp;name=MM4.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GEODON 		
					</strong><br><span class="contentTableReg">ziprasidone mesylate injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61786-172(NDC:0049-3920)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ZIPRASIDONE MESYLATE</strong> (ZIPRASIDONE) </td>
<td class="formItem">ZIPRASIDONE</td>
<td class="formItem">20 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHANESULFONIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SULFOBUTYLETHER .BETA.-CYCLODEXTRIN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61786-172-01</td>
<td class="formItem">1 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020919</td>
<td class="formItem">02/13/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8fc063a0-fa15-479f-9b80-041bcbe1ba07</div>
<div>Set id: 036db1f2-52b3-42a0-acf9-817b7ba8c724</div>
<div>Version: 1</div>
<div>Effective Time: 20150213</div>
</div>
</div> <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
